<div class=WordSection1>

<p class=MsoNormal align=center style='margin-top:12.0pt;margin-right:0in;
margin-bottom:12.0pt;margin-left:0in;text-align:center'><b><span
style='font-size:16.0pt;font-family:"Verdana","sans-serif"'>Session I: What
does dysferlin look like?</span></b></p>

<p class=MsoNormal align=center style='margin-top:12.0pt;margin-right:0in;
margin-bottom:12.0pt;margin-left:.5in;text-align:center;line-height:12.0pt'><i><span
style='font-size:8.5pt;font-family:"Verdana","sans-serif";color:black'>Examples:
Dysferlin molecular structure by EM or crystallography; chemical modifications;
domain structure; etc.</span></i></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif"'>&nbsp;</span></p>

<h1 style='margin-top:0in'><span style='font-size:12.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:navy'>Bryan Sutton, PhD</span></h1>

<p><span class=affiliation11><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>Department of Cell Physiology and Molecular Biophysics, Texas Tech
University Health Sciences Center, Lubbock, TX, USA</span></span><span
style='font-size:9.0pt;font-family:"Helvetica","sans-serif";color:black'><br>
</span><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif"'>roger.b.sutton@ttuhsc.edu<span
style='color:black'> </span></span></p>

<h2 style='margin-top:9.0pt'><span style='font-size:9.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:black'>Towards the Complete 3D
Structure of Dysferlin: Progress in X-ray and EM Studies</span></h2>

<p><span class=authors1><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>R. Bryan Sutton <sup>1</sup>, Kerry Fuson <sup>1</sup>, Danijela
Dukovski <sup>2</sup>, Thomas Walz <sup>2</sup></span></span><span
style='font-size:9.0pt;font-family:"Helvetica","sans-serif";color:black'> <br>
<span class=affiliations1><sup>1</sup>Department of Cell Physiology and
Molecular Biophysics, Texas Tech University Health Sciences Center, Lubbock,
TX, USA; <sup>2</sup>HHMI, Department of Cell Biology, Harvard Medical School,
Boston, MA, USA</span> </span></p>

<p><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:3.0pt'><img width=107 height=132
src="oral-abstracts-images/image001.jpg" align=left hspace=12
alt="Description: Sutton"><span style='font-size:9.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:black'>Point mutations within any
one of the seven C2 domains of dysferlin are sufficient to cause disease. To
understand the link between these mutations and disease, it is necessary to
know not only the high-resolution structures of the individual C2 domains but
also their organization in the context of the full-length protein. We have
already grown crystals of the C2A domain of human dysferlin that diffract to
2.4A resolution. We were able to solve the structure by using molecular
replacement techniques, and we are now working on the refinement and further
analysis of the C2A structure. Other C2 domains from dysferlin are also being
isolated for high-resolution structural studies. In parallel, we have produced
full-length mouse dysferlin and purified the protein to homogeneity. Images of
the purified protein obtained by negative stain electron microscopy (EM)
revealed mono-dispersed particles of homogeneous size. About 16,000 particles
were selected and classified into 200 groups. The resulting class averages show
that dysferlin can adopt many different conformations. In most of the class
averages, the linear molecule curls up, creating a circular appearance. Future
work will focus on establishing whether the different observed conformations
represent different functional states of dysferlin. </span></p>

<p class=MsoNormal style='margin-bottom:3.0pt'><span style='font-size:9.0pt;
line-height:115%;font-family:"Helvetica","sans-serif";color:black'>&nbsp;</span></p>

<h1 style='margin-top:0in'><span style='font-size:12.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:navy'>Sandra T Cooper, PhD</span></h1>

<p><span class=affiliation11><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>Institute for Neuroscience and Muscle Research, The Children's
Hospital at Westmead, Sydney, Australia</span></span><span style='font-size:
9.0pt;font-family:"Helvetica","sans-serif";color:black'><br>
</span><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif"'>sandrac3@chw.edu.au<span
style='color:black'> </span></span></p>

<h2 style='margin-top:9.0pt'><span style='font-size:9.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:black'>Ancient Eukaryotic Origins of
Ferlin Proteins</span></h2>

<p><span class=authors1><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>Angela Lek<sup>1,2</sup>, Monkol Lek <sup>1,2</sup>, Kathryn N.
North<sup>1,2</sup>, Sandra T. Cooper<sup>1,2</sup></span></span><span
style='font-size:9.0pt;font-family:"Helvetica","sans-serif";color:black'><br>
<span class=affiliations1><sup>1</sup>Institute for Neuroscience and Muscle
Research, The Children's Hospital at Westmead, Sydney, Australia; <sup>2</sup>Discipline
of Paediatrics and Child Health, University of Sydney, Australia</span> </span></p>

<p><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:12.0pt;background:white'><img width=100
height=140 src="oral-abstracts-images/image002.jpg" align=left
hspace=13 vspace=13
alt="Description: http://ankurdave.com/jainfoundation/conference2010/abstract-image.php?id=8"><span
style='font-size:9.0pt;font-family:"Helvetica","sans-serif"'>Our phylogenetic
analyses highlight the existence of ferlin-like proteins throughout eukaryotic
evolution, from unicellular organisms with only simple endomembrane systems,
through to humans. Almost all organisms possess two ferlin subtypes; one with
the DysF domain, and one lacking the DysF domain. Invertebrates generally
possess two ferlin genes, while most vertebrates have six ferlin genes. Common
to almost all ferlins is an N-terminal C2-FerI-C2 sandwich, a FerB motif, and
two C-terminal C2 domains adjacent to the transmembrane domain. Interestingly,
ferlins in the model organisms <i>C. elegans</i> and <i>D. melanogaster</i>
present as outgroups in the phylogenetic analysis, perhaps reflecting rapid
divergence of reproduction-related genes for specialised functions not shared
across the ferlin family.</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif"'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif"'>&nbsp;</span></p>

<p class=MsoNormal align=center style='margin-top:12.0pt;margin-right:0in;
margin-bottom:12.0pt;margin-left:0in;text-align:center'><b><span
style='font-size:16.0pt;font-family:"Verdana","sans-serif"'>Session II: Where
is dysferlin localized?</span></b></p>

<p class=MsoNormal align=center style='margin-top:12.0pt;margin-right:0in;
margin-bottom:12.0pt;margin-left:0in;text-align:center;line-height:12.0pt'><i><span
style='font-size:8.5pt;font-family:"Verdana","sans-serif";color:black'>Examples:
Sub-cellular location (e.g. surface, vesicles, t-tubules); trafficking; changes
in sub-cellular location in response to injury or other perturbations; kinetics
of location changes; expression in different cell types; etc.</span></i></p>

<h1 style='margin-top:0in'><span style='font-size:12.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:navy'>Robert J. Bloch, PhD</span></h1>

<p><span class=affiliation11><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>Department of Physiology, University of Maryland School of
Medicine, Baltimore, MD 21201</span></span><span style='font-size:9.0pt;
font-family:"Helvetica","sans-serif";color:black'><br>
</span><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif"'>rbloch@umaryland.edu<span
style='color:black'> </span></span></p>

<h2 style='margin-top:9.0pt'><span style='font-size:9.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:windowtext'>Localization of
Dysferlin</span></h2>

<p><span class=authors1><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>Robert J. Bloch <sup>1</sup></span></span><span style='font-size:
9.0pt;font-family:"Helvetica","sans-serif";color:black'> <br>
<span class=affiliations1><sup>1</sup>Department of Physiology, University of
Maryland School of Medicine, Baltimore, MD 21201</span></span></p>

<p><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>&nbsp;</span></p>

<p class=MsoNormal><img width=100 height=133
src="oral-abstracts-images/image003.jpg" align=left hspace=13
vspace=13
alt="Description: http://ankurdave.com/jainfoundation/conference2010/abstract-image.php?id=23"><span
style='font-size:9.0pt;line-height:115%;font-family:"Helvetica","sans-serif";
color:black'> </span><span style='font-size:9.0pt;line-height:115%;font-family:
"Helvetica","sans-serif"'>We have studied the subcellular distribution of
dysferlin in healthy and injured tibialis anterior muscles of the rat.  We
enhanced labeling of dysferlin with the Hamlet antibody after heat-induced
antigen retrieval.  Dysferlin is present at or near the sarcolemma and in a
reticulum surrounding the A-I junctions, where the t-tubules and junctional
sarcoplasmic reticulum (SR) are located.  We confirmed this localization with
antibodies to L-type Ca2+ channels (DHPR).  </span></p>

<h1 style='margin-top:0in'><span style='font-size:12.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:navy'>&nbsp;</span></h1>

<h1 style='margin-top:0in'><span style='font-size:12.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:navy'>&nbsp;</span></h1>

<h1 style='margin-top:0in'><span style='font-size:12.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:navy'>&nbsp;</span></h1>

<h1 style='margin-top:0in'><span style='font-size:12.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:navy'>&nbsp;</span></h1>

<h1 style='margin-top:0in'><span style='font-size:12.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:navy'>Steve Laval, DPhil</span></h1>

<p><span class=affiliation11><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>Institute of Human Genetics, Newcastle University, UK</span></span><span
style='font-size:9.0pt;font-family:"Helvetica","sans-serif";color:black'><br>
</span><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif"'>s.h.laval@ncl.ac.uk<span
style='color:black'> </span></span></p>

<h2 style='margin-top:9.0pt'><span style='font-size:9.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:black'>Sub-cellular Localization of
GFP-Dysferlin and Expression of Dysferlin in Myeloid Compartments</span></h2>

<p><span class=authors1><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>Lars Klinge <sup>1</sup>, Yen-Hui Chiu <sup>1</sup>, Steve Laval <sup>1</sup>,
Colker Straub<sup>1</sup>, Hanns Lochm</span></span><span style='font-size:
9.0pt;font-family:"Helvetica","sans-serif";color:black'>ü</span><span
class=authors1><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>ller<sup>1</sup>, Kate Bushby<sup>1</sup></span></span><span
style='font-size:9.0pt;font-family:"Helvetica","sans-serif";color:black'><br>
<span class=affiliations1><sup>1</sup>Institute of Human Genetics, Newcastle
University, UK</span></span></p>

<p><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><img width=100 height=75
src="oral-abstracts-images/image004.jpg" align=left hspace=13
vspace=13
alt="Description: http://ankurdave.com/jainfoundation/conference2010/abstract-image.php?id=2"><span
style='font-size:9.0pt;font-family:"Helvetica","sans-serif"'>We have expressed
GFP-tagged dysferlin constructs in various cell types and examined their
sub-cellular localisation. In C2C12 cells the full length dysferlin targets the
nascent T-tubule system and removal of any of the C2 domains changes the
localisation.&nbsp;Dysferlin trafficks to the plasma membrane in response to
wounding. In the myeloid lineage dysferlin is specifically expressed in the
non-classical monocyte population. </span></p>

<h1 style='margin-top:0in'><span style='font-size:12.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:navy'>&nbsp;</span></h1>

<h1 style='margin-top:0in'><span style='font-size:12.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:navy'>&nbsp;</span></h1>

<h1 style='margin-top:0in'><span style='font-size:12.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:navy'>Sandra T Cooper, PhD</span></h1>

<p><span class=affiliation11><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>Institute for Neuroscience and Muscle Research, The Children's
Hospital at Westmead, Sydney, Australia</span></span><span style='font-size:
9.0pt;font-family:"Helvetica","sans-serif";color:black'><br>
</span><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif"'>sandrac3@chw.edu.au<span
style='color:black'> </span></span></p>

<h2 style='margin-top:9.0pt'><span style='font-size:9.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:black'>Reduced Plasma Membrane
Expression of Dysferlin Mutants is Due to Accelerated Endocytosis Via a
Syntaxin-4 Associated Pathway.</span></h2>

<p><span class=authors1><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>Evesson FJ<sup>1,2</sup>, Lek AC <sup>1,2</sup>, Peat RA<sup>,1</sup>,
Lemckert FA<sup>1,2</sup>, North KN<sup>1,2</sup>, Sandra T. Cooper<sup>1,2</sup></span></span><span
style='font-size:9.0pt;font-family:"Helvetica","sans-serif";color:black'><br>
<span class=affiliations1><sup>1</sup>Institute for Neuroscience and Muscle
Research, The Children's Hospital at Westmead, Sydney, Australia; <sup>2</sup>Discipline
of Paediatrics and Child Health, University of Sydney, Australia</span> </span></p>

<p><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify;line-height:normal'><img
width=100 height=140 src="oral-abstracts-images/image002.jpg"
align=left hspace=13 vspace=13
alt="Description: http://ankurdave.com/jainfoundation/conference2010/abstract-image.php?id=8"><span
style='font-size:9.0pt;font-family:"Helvetica","sans-serif"'>Our trafficking
studies have shown <span style='layout-grid-mode:line'>dysferlin is a
short-lived and transitory transmembrane protein, with a propensity for rapid
endocytosis when mutated, and an association with a syntaxin-4 endocytic
route.&nbsp; Dysferlin plasma membrane expression and endocytic rate is
regulated by the </span>C2B-FerI-C2C motif, with a critical role identified for
C2C.&nbsp; We show that rapid endocytosis and endosomally-driven degradation is
also a feature of patient missense mutant L344P, introducing accelerated
endosomal-directed degradation as a new basis for protein lability of dysferlin
missense mutants in dysferlinopathy. <span style='layout-grid-mode:line'>Our
results </span>establish a transient biology for dysferlin, relevant to
emerging patient therapeutics targeting dysferlin replacement.</span></p>

<h1 style='margin-top:0in'><span style='font-size:12.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:navy'>&nbsp;</span></h1>

<h1 style='margin-top:0in'><span style='font-size:12.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:navy'>Gillian Butler-Browne, PhD</span></h1>

<p><span class=affiliations1><i><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>UMR S 974 Inserm – Institut de Myologie, Paris, France</span></i></span><span
style='font-size:9.0pt;font-family:"Helvetica","sans-serif";color:black'><br>
</span><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif"'>gillian.butler-browne@upmc.fr</span></p>

<h2 style='margin-top:9.0pt'><span style='font-size:9.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:black'>Are Secreted Microvesicles a
Novel Mechanism of Communication for Skeletal Muscle?</span></h2>

<p><span class=authors1><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>Marie-Catherine Le Bihan<sup>1</sup>, Anne Bigot <sup>1</sup>, </span></span><span
style='font-size:9.0pt;font-family:"Helvetica","sans-serif";color:black'>Søren
Skov Jensen<span class=authors1><sup>2</sup>, Adelina Rogowska-Wrzesinska<sup>2</sup>,
Jeanne Lain</span>é<span class=authors1><sup>1</sup>, Vincent Gache<sup>3</sup>,
Jayne Dennis<sup>4</sup>, Ole N</span>ørregaard Jensen<span class=authors1> <sup>2</sup>,
</span>Thomas Voit<span class=authors1><sup>1</sup>, Vincent Mouly<sup>1</sup>,
Gary R. Coulton<sup>4</sup>, Gillian Butler-Browne<sup>1,5</sup></span><br>
<span class=affiliations1><sup>1</sup>UMR S 974 Inserm – Institut de Myologie,
Paris, France; <sup>2</sup>Department of Biochemistry and Molecular Biology,
University of Southern Denmark, Odense, Denmark; <sup>3</sup> UMR S 787 Inserm,
</span></span><span lang=DA style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>Université Pierre et Marie Curie Paris VI</span><span
class=affiliations1><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'> Paris, France; <sup>4</sup>St. George’s Medical Biomics Centre,
St. George’s, University of London, London SW17 0RE, UK; <sup>5</sup>Correspondence
should be address to G.B.B. (e-mail: Gillian.butler-browne@upmc.fr)</span></span></p>

<p><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify;line-height:normal'><img
width=105 height=131 src="oral-abstracts-images/image005.jpg"
align=left hspace=12 alt="Description: Gill"><span style='font-size:9.0pt;
font-family:"Helvetica","sans-serif";color:black'>Communication between cells
mainly involves secretion of proteins binding to receptors on neighbouring
cells to elicit intracellular changes. </span><span style='font-size:9.0pt;
font-family:"Helvetica","sans-serif"'>Secreted proteins (“secretome”) regulate
activation, proliferation and differentiation of muscle progenitors (satellite
cells). We show that differentiating human muscle cells <i>in vitro</i> release
not only a plethora of soluble secreted proteins through conventional secretory
mechanisms but also complex protein/nucleic acid cargos via membrane
microvesicle (MVs) shedding. The soluble “secretome” contains 254
proteins/peptides with signalling potential including 45 previously implicated
in myogenesis. Many more have proven roles in modulating a range of other cell
types, implying a much broader role for myoblasts in regulating skeletal muscle
homeostasis and remodelling <i>in vivo</i>. We characterized the protein and
RNA content of these two types of muscle-derived secreted MVs and demonstrate
that they can dock and fuse differentially with adjacent muscle cells.
Moreover, we provide evidence for the intercellular exchange of a functional
protein cargo, alkaline phosphatase activity, to target cells following
microvesicle uptake. Thus, muscle-derived MVs may act <i>in vivo</i> as
“physiological liposomes” delivering protein/RNA cargo to target cells acting
in concert with soluble signalling molecules to modulate complex intercellular
signalling networks during muscle regeneration. We have shown that dysferlin is
one of the proteins of these MV’s. We will now study the formation and function
of these MV’s in the different dysferlin cell lines which have been generated
in our laboratory by Vincent Mouly.</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
style='font-size:9.0pt;font-family:"Helvetica","sans-serif"'>&nbsp;</span></p>

<b><span style='font-size:16.0pt;line-height:115%;font-family:"Verdana","sans-serif"'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal><b><span style='font-size:16.0pt;line-height:115%;
font-family:"Verdana","sans-serif"'>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='margin-top:12.0pt;margin-right:0in;
margin-bottom:12.0pt;margin-left:0in;text-align:center'><b><span
style='font-size:16.0pt;font-family:"Verdana","sans-serif"'>Session III: What
happens when dysferlin is missing?</span></b></p>

<p class=MsoNormal align=center style='margin-top:12.0pt;margin-right:0in;
margin-bottom:12.0pt;margin-left:0in;text-align:center;line-height:12.0pt'><i><span
style='font-size:8.5pt;font-family:"Verdana","sans-serif";color:black'>Examples:
Imaging of muscle sections; characterization of muscle membrane defects;
comparison of number and location of intracellular vesicles; T-tubule
structure; etc.</span></i></p>

<h1 style='margin-top:0in'><span style='font-size:12.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:navy'>&nbsp;</span></h1>

<h1 style='margin-top:0in'><span style='font-size:12.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:navy'>Miranda D. Grounds, PhD</span></h1>

<p><span class=affiliation11><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>School of Anatomy &amp; Human Biology, the University of Western
Australia, Australia </span></span><span style='font-size:9.0pt;font-family:
"Helvetica","sans-serif";color:black'><br>
</span><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif"'>kmag@stanford.edu<span
style='color:black'> </span></span></p>

<h2 style='margin-top:9.0pt'><span style='font-size:9.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:black'>Impact of Muscle Growth on
Onset of Dysferlinopathy</span></h2>

<p><span class=authors1><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>Miranda D. Grounds <sup>1,</sup></span></span><span
style='font-size:9.0pt;font-family:"Helvetica","sans-serif";color:black'><br>
<span class=affiliations1><sup>1</sup></span><span class=affiliation11> School
of Anatomy &amp; Human Biology, the University of Western Australia, Perth
6009, Western Australia, Australia</span></span></p>

<p><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:3.0pt'><img width=100 height=132
src="oral-abstracts-images/image006.jpg" align=left hspace=13
vspace=13
alt="Description: http://ankurdave.com/jainfoundation/conference2010/abstract-image.php?id=5"><span
style='font-size:9.0pt;line-height:115%;font-family:"Helvetica","sans-serif"'>It
is proposed that the properties of growing compared with adult sarcolemma can
influence the susceptibility to different gene defects[1]. For example,
Duchenne Muscular Dystrophy (DMD) is a paediatric disease and myofibre necrosis
is exacerbated during the growth phase in humans and the animal (mouse and dog)
models of DMD, yet in striking comtrast,  dysferlinopathies do not manifest until
just after the main growth phase ceases in humans and mice: why is this so? 
The idea that the response of sarcolemma of growing myotubes and young
myofibres (during development, regeneration and in culture) is very different
to that of sarcolemma of mature homeostatic myofibres of (uninjured) adult
muscles is explored. This concept has important consequences for selection of
models to study muscle diseases. </span></p>

<p class=MsoPlainText><span style='font-size:11.0pt;font-family:"Calibri","sans-serif"'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:3.0pt'><span style='font-size:9.0pt;
line-height:115%;font-family:"Helvetica","sans-serif"'>1.      Grounds MD.
(2008) Two tiered hypotheses for Duchenne Muscular Dystrophy.  Cellular and Molecular
Life Sciences 65:1621-5</span></p>

<h1 style='margin-top:0in'><span style='font-size:12.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:red'>&nbsp;</span></h1>

<h1 style='margin-top:0in'><span style='font-size:12.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:navy'>Bradley Williams, PhD</span></h1>

<p><span class=affiliation11><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>Jain Foundation, Bellevue, WA</span></span><span style='font-size:
9.0pt;font-family:"Helvetica","sans-serif";color:black'><br>
</span><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif"'>bwilliams@jain-foundation.org<span
style='color:black'> </span></span></p>

<p><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>&nbsp;</span></p>

<h2 style='margin-top:0in'><span style='font-size:9.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:black'>Age Range Distribution of
Clinical Onset and Influence of Gender and Mutation Type in dysferlinopathy</span><span
style='font-size:12.0pt;line-height:115%;font-family:"Times New Roman","serif"'>
</span></h2>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt'><span
class=authors1><span style='font-size:9.0pt;line-height:115%;font-family:"Helvetica","sans-serif";
color:black'>Bradley A. Williams<sup>1</sup>, Laura E. Rufibach<sup>1</sup>,
Esther Hwang<sup>1</sup>, Sahana Somasegar<sup>1</sup>, Plavi Mittal<sup>1</sup></span></span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt'><span
class=affiliations1><sup><span style='font-size:9.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:black'>1</span></sup></span><span
class=affiliation11><span style='font-size:9.0pt;line-height:115%;font-family:
"Helvetica","sans-serif";color:black'> Jain Foundation, Bellevue, WA</span></span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt'><b><span
style='font-size:12.0pt;line-height:115%;font-family:"Times New Roman","serif"'>&nbsp;</span></b></p>

<p class=MsoNormal><img width=97 height=113
src="oral-abstracts-images/image007.jpg" align=left hspace=12
alt="Description: 48-Brad"><span style='font-size:9.0pt;line-height:115%;
font-family:"Helvetica","sans-serif"'>Dysferlinopathy typically involves onset
of clinical symptoms in adolescence or early adulthood, but only rarely in
childhood. We analyzed the clinical history of 420 dysferlinopathy patients
(321 genetically confirmed) to determine the influence of gender and mutation
type on the age of clinical onset.  About 77% of patients in the cohort had
onset in the age range of 15-30, with about 12% having onset before age 15 and
11% after age 30. The average age of onset and rate of progression is similar
for females and males, but females are more likely to have symptoms in before
age 16 or after age 40, while 45% of male patients (25% of females) have onset
between ages 17-20.  One possible explanation for the large percentage of
patients with onset of symptoms during adolescence, and the gender difference,
is a correlation of onset of symptoms with cessation of growth.</span></p>

<p class=MsoNormal>&nbsp;</p>

<span style='font-size:12.0pt;line-height:115%;font-family:"Helvetica","sans-serif";
color:navy'><br clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal><b><span style='font-size:12.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:navy'>&nbsp;</span></b></p>

<h1 style='margin-top:0in'><span style='font-size:12.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:navy'>Robert J. Bloch, PhD</span></h1>

<p><span class=affiliation11><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>Department of Physiology, University of Maryland School of
Medicine, Baltimore, MD 21201</span></span><span style='font-size:9.0pt;
font-family:"Helvetica","sans-serif";color:black'><br>
</span><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif"'>rbloch@umaryland.edu<span
style='color:black'> </span></span></p>

<h2 style='margin-top:9.0pt'><span style='font-size:9.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:black'>Young A/J Muscle Shows
Pathological Changes Similar to Dystrophic Muscle Only After
Contraction-Induced Injury</span></h2>

<p><span class=authors1><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>Robert J. Bloch <sup>1</sup></span></span><span style='font-size:
9.0pt;font-family:"Helvetica","sans-serif";color:black'> <br>
<span class=affiliations1><sup>1</sup>Department of Physiology, University of Maryland
School of Medicine, Baltimore, MD 21201</span></span></p>

<p><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>&nbsp;</span></p>

<p class=MsoNormal><img width=100 height=133
src="oral-abstracts-images/image008.jpg" align=left hspace=13
vspace=13
alt="Description: http://ankurdave.com/jainfoundation/conference2010/abstract-image.php?id=23"><span
style='font-size:9.0pt;line-height:115%;font-family:"Helvetica","sans-serif"'> The
tibialis anterior muscle of A/J mice appears similar to control A/WySnJ muscle,
except that A/J muscle has more centrally nucleated fibers (CNFs).  Following <i>in
vivo</i> injury by small- or large-strain lengthening contractions, A/J and
A/WySnJ muscles lose a similar level of contractile torque and show similar
numbers of necrotic fibers.  However, many hours and several days following
injury, many necrotic fibers invaded by macrophages appear in the A/J muscle,
compared to controls, and recovery is slower than in the A/WySnJ due to the
need for myogenesis to replace fibers that are killed over the hours and days
following injury.    </span></p>

<h1 style='margin-top:0in'><span style='font-size:11.0pt;line-height:115%;
font-family:"Calibri","sans-serif";color:windowtext;font-weight:normal'>&nbsp;</span></h1>

<h1 style='margin-top:0in'><span style='font-size:11.0pt;line-height:115%;
font-family:"Calibri","sans-serif";color:windowtext;font-weight:normal'>&nbsp;</span></h1>

<h1 style='margin-top:0in'><span style='font-size:12.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:navy'>Katie Maguire, PhD</span></h1>

<p><span class=affiliation11><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>Department of Neurology, Stanford University, Palo Alto, CA, USA</span></span><span
style='font-size:9.0pt;font-family:"Helvetica","sans-serif";color:black'><br>
</span><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif"'>kmag@stanford.edu<span
style='color:black'> </span></span></p>

<h2 style='margin-top:9.0pt'><span style='font-size:9.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:black'>Monitoring the Progression of
LGMD2B In Vivo</span></h2>

<p><span class=authors1><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>Katie Maguire <sup>1,2</sup>, Thomas Rando <sup>1,2</sup></span></span><span
style='font-size:9.0pt;font-family:"Helvetica","sans-serif";color:black'> <br>
<span class=affiliations1><sup>1</sup>Department of Neurology, Stanford
University, Palo Alto, CA, USA; <sup>2</sup>Veterans Affairs Health Care
System, Palo Alto, CA, US</span> </span></p>

<p><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>&nbsp;</span></p>

<p class=MsoNormal><img width=100 height=139
src="oral-abstracts-images/image009.jpg" align=left hspace=13
vspace=13
alt="Description: http://ankurdave.com/jainfoundation/conference2010/abstract-image.php?id=60"><span
style='font-size:9.0pt;line-height:115%;font-family:"Helvetica","sans-serif"'>One
of the major limitations to the study of therapeutic agents for the treatment
of muscular dystrophies such as LGMD2B is the absence of reliable markers of
disease activity in the living mouse.  The snapshots of muscle histology, while
perhaps reflecting the effectiveness or lack thereof for candidate drugs, are
labor-intensive, cumbersome, and difficult to quantify.  We have bred novel
dysferlin-deficient reporter mouse strains in which muscle regeneration and
muscle degeneration can effectively be measured over time <i>in vivo</i>.  The
muscle regeneration reporter mouse expresses an estrogen-responsive <i>Cre-</i>recombinase
under the control of the Pax7 locus and a luciferase reporter gene that is
Cre-dependent. Thus, in the presence of tamoxifen, luciferase is expressed only
in muscle satellite cells and all of their progeny. Each time the muscle
undergoes regeneration, luciferase-positive satellite cells give rise to
progeny which also express the gene.  We show that there is a statistically
significant increase in muscle regeneration in the absence of dysferlin over
time by measuring an increase in bioluminescence activity.  Intriguingly, we
find that this manifestation of LGMD2B occurs very early in the life of the
dysferlin-deficient mouse, before histological evidence of a muscular dystrophy
appears.  Muscle degeneration in another reporter strain is measured by the
loss of luciferase signal in mature myofibers. In this case, the induction of
luciferase expression is dependent on an MRF4-driven estrogen-responsive Cre
and, again, the administration of tamoxifen to the mice.  Proof of concept
experiments in these animals have shown a dramatic decrease in luciferase
signal after a muscle injury, supporting the contention that this reporter
mouse will be an additional useful tool for screening drugs and molecular
treatments for LGMD2B. </span></p>

<h1 style='margin-top:0in'><span style='font-size:12.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:navy'>&nbsp;</span></h1>

<span style='font-size:12.0pt;line-height:115%;font-family:"Helvetica","sans-serif";
color:navy'><br clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal><b><span style='font-size:12.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:navy'>&nbsp;</span></b></p>

<h1 style='margin-top:0in'><span style='font-size:12.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:navy'>Simone Spuler, MD</span></h1>

<p><span class=affiliation11><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif"'>Muscle
Research Unit, Experimental and Clinical Research Center, Charité and Max
Delbrück Center, Berlin, Germany</span></span><span style='font-size:9.0pt;
font-family:"Helvetica","sans-serif"'><br>
</span><a href="mailto:simone.spuler@charite.de"><span class=email><span
style='font-size:9.0pt;font-family:"Helvetica","sans-serif";color:windowtext;
text-decoration:none'>simone.spuler@charite.de</span></span></a><span
style='font-size:9.0pt;font-family:"Helvetica","sans-serif"'> </span></p>

<h2 style='margin-top:9.0pt'><span style='font-size:9.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:windowtext'>Endurance Exercise in
Young Dysferlin-deficient Mice</span></h2>

<p><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif"'>Verena
Schöwel*<sup>1</sup>, Stephanie Adams*<sup>1</sup>, Stephanie Meier<sup>1</sup>,
Isabelle Richard<sup>1,2</sup>, Simone Spuler<sup>1</sup><br>
<span class=affiliations1><sup>1</sup>Muscle Research Unit, Experimental and
Clinical Research Center, Charité and Max Delbrück Center, Berlin, Germany; <sup>2</sup>Genethon,
France</span> </span></p>

<p><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif"'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><img width=95 height=105
src="oral-abstracts-images/image010.jpg" align=left hspace=13
vspace=13 alt="Description: sspuler photo"><span style='font-size:9.0pt;
font-family:"Helvetica","sans-serif"'>Patients with dysferlinopathy have a
normal motor development in childhood. Occasionally, they are very athletic
prior to the onset of symptoms in the third decade of life. There is anecdotal
evidence that patients who have been very active physically in adolescence may
experience a more severe course of disease. We asked how young
dysferlin-deficient mice would perform during endurance excercise and how
excercise would affect muscle histology. 4 week old BLA/J mice and C57BL/6 mice
as controls were trained on an ascending treadmill for one week. Total running
distance and number of fall-backs to the bottom of the device were measured.
Muscle histology was taken. We show that BLA/J mice have a slightly better
physical performance than controls. Muscle histology, however, demonstrates
fiber necrosis, regeneration and increased number of central nuclei in
excercised BLA/J mice. C57BL/6 and sedentary young BLA/J display normal muscle
histology. We conclude that excercise may accelerate muscle deterioration in
dysferlinopathy.</span></p>

<p class=MsoNormal><span style='font-size:9.0pt;line-height:115%;font-family:
"Helvetica","sans-serif"'>&nbsp;</span></p>

<b><span style='font-size:16.0pt;line-height:115%;font-family:"Verdana","sans-serif"'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal><b><span style='font-size:16.0pt;line-height:115%;
font-family:"Verdana","sans-serif"'>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='margin-top:12.0pt;margin-right:0in;
margin-bottom:12.0pt;margin-left:0in;text-align:center'><b><span
style='font-size:16.0pt;font-family:"Verdana","sans-serif"'>Session IV: What
does dysferlin do?</span></b></p>

<p class=MsoNormal align=center style='margin-top:12.0pt;margin-right:0in;
margin-bottom:12.0pt;margin-left:0in;text-align:center;line-height:12.0pt'><i><span
style='font-size:8.5pt;font-family:"Verdana","sans-serif";color:black'>Examples:
Dysferlin's role in membrane repair, vesicle fusion, secretion,
exo/endocytosis, etc.</span></i></p>

<h1 style='margin-top:0in'><span style='font-size:12.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:navy'>&nbsp;</span></h1>

<h1 style='margin-top:0in'><span style='font-size:12.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:navy'>Robert J. Bloch, PhD</span></h1>

<p><span class=affiliation11><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>Department of Physiology, University of Maryland School of
Medicine, Baltimore, MD 21201</span></span><span style='font-size:9.0pt;
font-family:"Helvetica","sans-serif";color:black'><br>
</span><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif"'>rbloch@umaryland.edu<span
style='color:black'> </span></span></p>

<h2 style='margin-top:9.0pt'><span style='font-size:9.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:windowtext'>Dysferlin Maintains the
Integrity of T-Tubules, and Helps Restore Homeostasis and Prevent Myofiber
Death After Injury</span></h2>

<p><span class=authors1><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>Robert J. Bloch <sup>1</sup></span></span><span style='font-size:
9.0pt;font-family:"Helvetica","sans-serif";color:black'> <br>
<span class=affiliations1><sup>1</sup>Department of Physiology, University of
Maryland School of Medicine, Baltimore, MD 21201</span> </span></p>

<p><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>&nbsp;</span></p>

<p class=MsoNormal><img width=100 height=133
src="oral-abstracts-images/image008.jpg" align=left hspace=13
vspace=13
alt="Description: http://ankurdave.com/jainfoundation/conference2010/abstract-image.php?id=23"><span
style='font-size:9.0pt;line-height:115%;font-family:"Helvetica","sans-serif"'> We
hypothesize that dysferlin acts intracellularly to protect muscle from damage
caused by contraction, and to promote recovery after injury without the need to
replace fibers by myogenesis.  We induced injury in young Sprague-Dawley rats
with 10 large-strain lengthening contractions, which reduced contractile torque
by ~50% and from which recovery occurs within ~3 days, without significant
inflammation or myogenesis.    Immediately after injury, dysferlin in the
myoplasm concentrates at numerous foci that are likely to be altered segments
of the t-tubular system, and its labeling intensity increases in &gt;25% of the
fibers.  </span></p>

<p class=MsoNormal><span style='font-size:9.0pt;line-height:115%;font-family:
"Helvetica","sans-serif"'>&nbsp;</span></p>

<h1 style='margin-top:0in'><span style='font-size:12.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:navy'>Elisabeth R Barton, PhD</span></h1>

<p><span class=affiliation11><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>University of Pennsylvania</span></span><span style='font-size:
9.0pt;font-family:"Helvetica","sans-serif";color:black'><br>
</span><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif"'>erbarton@dental.upenn.edu<span
style='color:black'> </span></span></p>

<h2 style='margin-top:9.0pt'><span style='font-size:9.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:black'>Role of Dysferlin In
Susceptibility to Contraction-Induced Injury</span></h2>

<p><span class=authors1><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>Elisabeth Barton <sup>1</sup>, Magdalena Sikora <sup>1</sup>,
Zuozhen Tian <sup>1</sup>, H Lee Sweeney <sup>1</sup></span></span><span
style='font-size:9.0pt;font-family:"Helvetica","sans-serif";color:black'> <br>
<span class=affiliations1><sup>1</sup>University of Pennsylvania</span> </span></p>

<p><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:3.0pt'><img width=100 height=119
src="oral-abstracts-images/image011.jpg" align=left hspace=13
vspace=13
alt="Description: http://ankurdave.com/jainfoundation/conference2010/abstract-image.php?id=59"><span
style='font-size:9.0pt;line-height:115%;font-family:"Helvetica","sans-serif";
color:black'>Mouse models for dysferlin deficiency provide a platform to study
physiological deficits associated with the disease. We previously showed that
the diaphragm display early functional deficits including loss of strength and
increased susceptibility to contractile damage, whereas the limb muscles have
little functional pathology. We tested the hypothesis that in the absence of
extracellular calcium, diaphragm muscles from wildtype mice would also display
comparable susceptibility to eccentric contraction injury due to the inhibition
of dysferlin function. Isolated muscles were subjected to functional testing in
Ringer's solution containing 0.25 mM Calcium (10% of normal levels).
Surprisingly, the stability of the diaphragm muscle preparation decreased
dramatically even without eccentric contractions. However the EDL muscles could
withstand low calcium conditions and remained stable for the duration of the
experiment. Thus, sarcolemmal calcium handling appears to be significantly
different in these muscles, and suggests that divergence in the regulation of
calcium handling may modulate the severity of the disease.</span></p>

<p class=MsoNormal style='margin-bottom:3.0pt'><span style='font-size:9.0pt;
line-height:115%;font-family:"Helvetica","sans-serif";color:black'>&nbsp;</span></p>

<h1 style='margin-top:0in'><span style='font-size:12.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:navy'>Sandra T Cooper, PhD</span></h1>

<p><span class=affiliation11><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>Institute for Neuroscience and Muscle Research, The Children's
Hospital at Westmead, Sydney, Australia</span></span><span style='font-size:
9.0pt;font-family:"Helvetica","sans-serif";color:black'><br>
</span><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif"'>sandrac3@chw.edu.au<span
style='color:black'> </span></span></p>

<h2 style='margin-top:9.0pt'><span style='font-size:9.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:black'>Dysferlin and Acute Membrane
Resealing; Is This its Real Job?</span></h2>

<p><span class=authors1><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>Angela Lek <sup>1,2</sup>, Frances J Evesson <sup>1,2</sup>,
Joanne Hawkes <sup>1</sup>, Frances A Lemckert <sup>1,2</sup>, Fabienne Brillot
<sup>1,2</sup>, Russell C Dale <sup>1,2</sup>, North N Kathryn <sup>1,&#8319;</sup></span></span><span
style='font-size:9.0pt;font-family:"Helvetica","sans-serif";color:black'>,
Sandra T. Cooper<span class=authors1> <sup>1,2</sup></span><br>
<span class=affiliations1><sup>1</sup>Institute for Neuroscience and Muscle
Research, The Children's Hospital at Westmead, Sydney, Australia; <sup>2</sup>Discipline
of Paediatrics and Child Health, University of Sydney, Australia</span> </span></p>

<p><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:3.0pt'><img width=100 height=140
src="oral-abstracts-images/image002.jpg" align=left hspace=13
vspace=13
alt="Description: http://ankurdave.com/jainfoundation/conference2010/abstract-image.php?id=8"><span
style='font-size:9.0pt;line-height:115%;font-family:"Helvetica","sans-serif";
color:black'> </span><span style='font-size:9.0pt;line-height:115%;font-family:
"Helvetica","sans-serif"'>We have studied the consequences of dysferlin
deficiency and dysferlin overexpression upon acute membrane resealing in
cultured skeletal myotubes.&nbsp; Our studies employ mechanical (microparticle ballistics) and detergent-based (saponin) membrane damage. Our detergent-based
damage assay demonstrates that dysferlin knock-down cells have a modest
resealing defect, most profoundly observed at extremes of damage.&nbsp; In
contrast, dysferlin overexpression significantly impairs membrane resealing, as
does expression of dysferlin mutants.&nbsp; Using ballistics, we have studied
the calcium- and dysferlin-dependent recruitment of dysferlin-interacting
proteins MG53 and annexin A1 to sites of membrane injury.&nbsp; We have no
evidence that dysferlin is subject to regulated exocytosis in response to a
membrane injury event.&nbsp; Our data therefore suggests that it is dysferlin
already localised within the plasma membrane that plays a key role in membrane
resealing at the time of injury, and/or, that other functions of dysferlin
secondarily impact membrane resealing.</span></p>

<h1 style='margin-top:0in'><span style='font-size:12.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:navy'>&nbsp;</span></h1>

<h1 style='margin-top:0in'><span style='font-size:12.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:navy'>Simone Spuler, MD</span></h1>

<p><span class=affiliation11><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif"'>Muscle
Research Unit, Experimental and Clinical Research Center, Charité and Max
Delbrück Center, Berlin, Germany</span></span><span style='font-size:9.0pt;
font-family:"Helvetica","sans-serif"'><br>
</span><a href="mailto:simone.spuler@charite.de"><span class=email><span
style='font-size:9.0pt;font-family:"Helvetica","sans-serif";color:windowtext;
text-decoration:none'>simone.spuler@charite.de</span></span></a><span
style='font-size:9.0pt;font-family:"Helvetica","sans-serif"'> </span></p>

<h2 style='margin-top:9.0pt'><span style='font-size:9.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:windowtext'>Laser Wounding of
Primary Human Myotubes</span></h2>

<p><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif"'>Andreas
Marg*<span class=authors1><sup>1,2</sup></span>, Verena Schöwel*<span
class=authors1><sup>1,2</sup></span>, <span class=authors1>Simone Spuler <sup>1,&#8319;</sup></span></span></p>

<p><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif"'>*All
contributed equally<br>
<span class=affiliations1><sup>1</sup>Muscle Research Unit, Experimental and
Clinical Research Center, Charité and Max Delbrück Center, Berlin, Germany; <sup>2</sup>Muscle
Physiology, Max Delbrück Center, Berlin, Germany</span> </span></p>

<p><img width=95 height=105
src="oral-abstracts-images/image012.jpg" align=left hspace=12
alt="Description: sspuler photo"><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif"'>&nbsp;</span></p>

<p class=MsoNormal><span style='font-size:9.0pt;line-height:115%;font-family:
"Helvetica","sans-serif"'>Murine intact muscle fibers can reliably be wounded
by laser and dye influx can be quantified. This assay is presently the most
accepted assay to quantify membrane repair. Only limited experience exists
applying the „laser-wounding-assay“ to cultured primary myotubes that lack the
strict sarcomer organisation of mature muscle. We performed laser wounding on
primary human normal and dysferlin-deficient myotubes 7 days after fusion. </span><span
lang=EN-GB style='font-size:9.0pt;line-height:115%;font-family:"Helvetica","sans-serif"'>Before
laser wounding cells were plated in Tyrode solution with 2.5 &#956;M FM 1-43
with or without 2 mM Ca<sup>2+</sup>. Myotubes were wounded by irritating a 2,5
x 2,5 &#956;m boundary area of the plasma membrane at </span><span
style='font-size:9.0pt;line-height:115%;font-family:"Helvetica","sans-serif"'>50%
maximum power (30-mW argon-laser) for 37s using a Zeiss-LSM 510 META confocal
microscope with a 63x oil immersion lens. Digital images were processed using
the Zeiss LSM Image Browser software. To calculate the fluorescent intensity an
area of 10 x 10 &#956;m directly adjacent to the injury site was used. The
initial fluorescence intensity was set to zero. All experiments were repeated
at least 6 times. Dye influx into primary human myotubes was readily visible in
the absence of calcium and in dysferlin-deficient myotubes. The distribution of
the dye was more diffuse in the myotube than in intact muscle fibers. This is
probably due to a lesser extent of intracellular compartimentalization in
myotubes.</span></p>

<h1 style='margin-top:0in'><span style='font-size:9.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:black;font-weight:normal'>&nbsp;</span></h1>

<h1 style='margin-top:0in'><span style='font-size:12.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:navy'>Isabelle Richard, PhD</span></h1>

<p><span class=affiliation11><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>Généthon, CNRS, Evry, France</span></span><span style='font-size:
9.0pt;font-family:"Helvetica","sans-serif";color:black'><br>
</span><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif"'>richard@genethon.fr<span
style='color:black'> </span></span></p>

<h2 style='margin-top:9.0pt'><span style='font-size:9.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:windowtext'>Pathogenicity of Dysferlin
Deficiency May Not Directly be Related to Membrane Resealing Impairment</span></h2>

<p><span class=authors1><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif"'>William
Lostal <sup>1</sup>, François Monjaret <sup>1</sup>, Nathalie Bourg <sup>1</sup>,
Carinne Roudaut <sup>1</sup>, Marina Pryadkina <sup>1</sup>, Katsuya Miyake <sup>4</sup>,
Paul Mcneil<sup>4</sup>, Marc Bartoli <sup>3</sup>, Martin Krahn <sup>3</sup>,
Nicolas Levy<sup>3</sup>, Perrinne Borel<sup>1</sup>, Daniel Stockholm<sup>1</sup>,
Rumaisa Bashir<sup>5</sup>, Isabelle Richard <sup>1</sup></span></span><span
style='font-size:9.0pt;font-family:"Helvetica","sans-serif"'> <br>
<span class=affiliations1><sup>1</sup>Généthon, CNRS, Evry, France; <sup>2</sup>Univ.
of Maryland, Baltimore, MD, USA; <sup>3</sup>Hôpital de la Timone and Inserm
UMR910, Université de la Méditerranée, Marseille, France; <sup>4</sup>Medical
College of Georgia, Augusta, Georgia, USA; <sup>5</sup>School of Biological and
Biomedical Sciences, University of Durham, Durham, UK</span> </span></p>

<p><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif"'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:3.0pt'><img width=100 height=150
src="oral-abstracts-images/image013.jpg" align=left hspace=13
vspace=13
alt="Description: http://ankurdave.com/jainfoundation/conference2010/abstract-image.php?id=6"><span
style='font-size:9.0pt;line-height:115%;font-family:"Helvetica","sans-serif"'> To
test the hypothesis that myoferlin, which is very homologous to dysferlin,
could be a good candidate for compensatory therapy in dysferlinopathies, we
constructed a transgenic mice over expressing myoferlin that we crossed with a
dysferlin deficient model. We observed that myoferlin overexpression
compensates for membrane fusion defect of dysferlin deficiency but does not
lead to any improvement in muscle histology. Similar results were obtained
after AAV-mediated transfer of a miniform of dysferlin. All these data suggest
that the pathogenicity of dysferlin deficiency may not be related directly to
impairment of membrane resealing.</span></p>

<h1 style='margin-top:0in'><span style='font-size:12.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:navy;background:yellow'>&nbsp;</span></h1>

<h1 style='margin-top:0in'><span style='font-size:12.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:navy;background:yellow'>&nbsp;</span></h1>

<p class=MsoNormal style='margin-bottom:3.0pt'><span style='font-size:9.0pt;
line-height:115%;font-family:"Helvetica","sans-serif";color:black'>&nbsp;</span></p>

<h1 style='margin-top:0in'><span style='font-size:12.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:navy'>Steven Vogel, PhD</span></h1>

<p><span class=affiliation11><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>NIAAA, NIH, Rockville, MD, USA</span></span><span
style='font-size:9.0pt;font-family:"Helvetica","sans-serif";color:black'><br>
</span><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif"'>stevevog@mail.nih.gov<span
style='color:black'> </span></span></p>

<h2 style='margin-top:9.0pt'><span style='font-size:9.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:black'>Membrane Wounding Triggers ATP
Release and Dysferlin Mediated Intercellular Calcium Signaling</span></h2>

<p><span class=authors1><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>Steven Vogel <sup>1</sup></span></span><span style='font-size:
9.0pt;font-family:"Helvetica","sans-serif";color:black'> <br>
<span class=affiliations1><sup>1</sup>NIAAA, NIH, Rockville, MD, USA</span> </span></p>

<p><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:3.0pt'><img width=100 height=150
src="oral-abstracts-images/image014.jpg" align=left hspace=13
vspace=13
alt="Description: http://ankurdave.com/jainfoundation/conference2010/abstract-image.php?id=13"><span
style='font-size:9.0pt;line-height:115%;font-family:"Helvetica","sans-serif";
color:black'>Dysferlin is a calcium-binding protein found in many different
cell types. It is required for membrane wound repair in muscle, but it is not
known if it has the same function in other cells. Here we report the activation
of an intercellular signaling pathway in sea urchin embryos by membrane
wounding that evokes calcium spikes in neighboring cells. This pathway was
mimicked by ATP application, and inhibited by apyrase, cadmium, and
&#969;-agatoxin-IVA. Microinjection of dysferlin antisense phosphorodiamidate
morpholino oligonucleotides blocked this pathway while control morpholinos did
not. Co-injection of mRNA encoding human dysferlin with the inhibitory
morpholino rescued signaling activity. We conclude that in embryos dysferlin
mediates calcium-triggered intercellular signaling in response to membrane
wounding. </span></p>

<p class=MsoNormal><span style='font-size:9.0pt;line-height:115%;font-family:
"Helvetica","sans-serif"'>    </span></p>

<h1 style='margin-top:0in'><span style='font-size:12.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:navy'>Paul S. Blank, PhD</span></h1>

<p><span class=affiliation11><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>Program in Physical Biology, Eunice Kennedy Schriver National
Institute of Child Health and Human Development, NIH, Bethesda, MD, USA</span></span><span
style='font-size:9.0pt;font-family:"Helvetica","sans-serif";color:black'><br>
</span><a href="mailto:blankp@mail.nih.gov"><span class=email><span
style='font-size:9.0pt;font-family:"Helvetica","sans-serif";color:black;
text-decoration:none'>blankp@mail.nih.gov</span></span></a><span
style='font-size:9.0pt;font-family:"Helvetica","sans-serif";color:black'> </span></p>

<h2 style='margin-top:9.0pt'><span style='font-size:9.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:black'>Intercellular Calcium
Signaling Absent in Dysferlin Deficient Myotubes</span></h2>

<p><span class=authors1><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>Paul S. Blank <sup>1</sup>, Glen Humphrey <sup>1</sup>, Elena
Mekhedov <sup>1</sup>, Joshua Zimmerberg <sup>1</sup></span></span><span
style='font-size:9.0pt;font-family:"Helvetica","sans-serif";color:black'> <br>
<span class=affiliations1><sup>1</sup>Program in Physical Biology, Eunice
Kennedy Schriver National Institute of Child Health and Human Development, NIH,
Bethesda, MD, USA</span> </span></p>

<p><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:3.0pt'><img width=100 height=83
src="oral-abstracts-images/image015.jpg" align=left hspace=13
vspace=13
alt="Description: http://ankurdave.com/jainfoundation/conference2010/abstract-image.php?id=68"><span
style='font-size:9.0pt;line-height:115%;font-family:"Helvetica","sans-serif";
color:black'>Myotubes from a dysferlin deficient, mouse, myogenic cell line
(GREG) were used to evaluate recovery from IR laser wounding. Over a range of
IR wounding parameters, GREG myotubes labeled with the calcium indicators
Fluo-4 and Fura Red, show changes in the normalized fluorescence intensity
ratio consistent with wounding and repair. There was no evidence of a calcium
response in neighboring myotubes. However, aware of the dysferlin dependent
signaling pathway in sea urchin embryos (Covian-Nares et. al 2010, J. Cell
Sci.), we examined membrane repair in C2C12 myotubes and confirmed the
existence of a bystander calcium response to wounding in dysferlin competent
myotubes. Since GREG cells are able to wound repair in the absence of
detectable dysferlin, the major observable difference between dysferlin
positive and negative myotubes is the loss of the bystander calcium response.
That neighboring myotubes respond to a wounded dysferlin positive cell suggests
that the exocytosis/secretion/release of a diffusible substance is an important
aspect of wound repair and that this release is dysferlin dependent. The timing
of the peak bystander response is dependent upon the distance from the wound
site. Preliminary data support the hypothesis that the number of participating
bystander cells in a field of view is dependent upon the degree of wounding;
larger wounds created using increased IR fluence recruit greater numbers of
bystanders. If the bystander response in myotubes uses the same mechanism as
that observed in urchins, then we expect the signaling to be occurring via a
purogenic pathway. Experiments to test this hypothesis are ongoing.</span></p>

<h1 style='margin-top:0in'><span style='font-size:12.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:navy'>&nbsp;</span></h1>

<h1 style='margin-top:0in'><span style='font-size:12.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:navy'>Elizabeth McNally, MD, PhD</span></h1>

<p><span class=affiliation11><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>Department of Medicine, The University of Chicago, Chicago, IL
60637 USA</span></span><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'><br>
</span><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif"'>ademonbreun@uchicago.edu<span
style='color:black'> </span></span></p>

<h2 style='margin-top:9.0pt'><span style='font-size:9.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:black'>Dysferlin Regulates Vesicle
Recycling in Myoblasts and Fibroblasts</span></h2>

<p><span class=authors1><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>Alexis R. Demonbreun <sup>1</sup>, Judy U. Earley <sup>1</sup>,
Peter Pytel <sup>2</sup>, Elizabeth M. McNally <sup>1,3,4,5</sup></span></span><span
style='font-size:9.0pt;font-family:"Helvetica","sans-serif";color:black'> <br>
<span class=affiliations1><sup>1</sup>Department of Medicine, The University of
Chicago, Chicago, IL 60637 USA; <sup>2</sup>Department of Pathology, The
University of Chicago, Chicago, IL 60637 USA; <sup>3</sup>Committee on
Developmental Biology, The University of Chicago, Chicago, IL 60637 USA; <sup>4</sup>Committee
on Genetics, The University of Chicago, Chicago, IL 60637 USA; <sup>5</sup>Department
of Human Genetics, The University of Chicago, Chicago, IL 60637 USA</span> </span></p>

<p><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:3.0pt'><img width=100 height=114
src="oral-abstracts-images/image016.jpg" align=left hspace=13
vspace=13
alt="Description: http://ankurdave.com/jainfoundation/conference2010/abstract-image.php?id=45"><span
style='font-size:9.0pt;line-height:115%;font-family:"Helvetica","sans-serif";
color:black'>Ferlin proteins mediate membrane fusion in response to calcium.
Loss of function mutations in dysferlin cause muscular dystrophy, and dysferlin
is implicated in resealing membrane disruption in myofibers. To understand how
dysferlin functions in muscle regeneration, we studied the role of dysferlin in
muscle growth. We found that dysferlin null myoblasts have a defect in
myoblast–to-myotube fusion resulting in smaller myotubes in culture. We studied
the effect of muscle growth in vivo in dysferlin null mice by infusing mice
with the growth stimulant insulin like growth factor (IGF1). Control IGF1
treated mice increased myofiber diameter by 30% as expected, while dysferlin
null muscles had no response to IGF1, indicating a defect in myofiber growth.
We found that myoblasts isolated from dysferlin null mice accumulate acidic,
LAMP2 positive vesicles. Additionally, dysferlin null myoblasts accumulate
transferrin-488 in the endocytic recycling compartment due to a delay in
endocytic recycling. Interestingly, fibroblasts lacking dysferlin also
accumulate acidic vesicles and transferrin, indicating that defective
fibroblast function may contribute to disease and may be suitable surrogate for
muscle cells. These data implicate dysferlin in multiple vesicle trafficking
events within the cell and suggest multiple pathways by which dysferlin
regulates muscle growth and repair. </span></p>

<p class=MsoNormal style='margin-bottom:3.0pt'><span style='font-size:9.0pt;
line-height:115%;font-family:"Helvetica","sans-serif";color:black'>&nbsp;</span></p>

<b><span style='font-size:16.0pt;line-height:115%;font-family:"Verdana","sans-serif"'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal><b><span style='font-size:16.0pt;line-height:115%;
font-family:"Verdana","sans-serif"'>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='margin-top:12.0pt;margin-right:0in;
margin-bottom:12.0pt;margin-left:0in;text-align:center'><b><span
style='font-size:16.0pt;font-family:"Verdana","sans-serif"'>Session V: What do
dysferlin partners do?</span></b></p>

<p class=MsoNormal align=center style='margin-top:12.0pt;margin-right:0in;
margin-bottom:12.0pt;margin-left:0in;text-align:center;line-height:12.0pt'><i><span
style='font-size:8.5pt;font-family:"Verdana","sans-serif";color:black'>Examples:
Identification of interacting proteins; conditions under which the interaction
takes place; role of the interacting proteins; role of other ferlin proteins
(e.g. myoferlin, otoferlin); etc.</span></i></p>

<h1 style='margin-top:0in'><span style='font-size:12.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:navy'>Silvère M van der Maarel, PhD</span></h1>

<p><span class=affiliation11><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>Department of Human Genetics, Leiden University Medical Center,
Leiden, Netherlands</span></span><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'><br>
</span><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif"'>maarel@lumc.nl<span
style='color:black'> </span></span></p>

<h2 style='margin-top:9.0pt'><span style='font-size:9.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:black'>Proteomic Analysis of the
Dysferlin Protein Complex Unveils its Importance for Sarcolemmal Maintenance
and Integrity</span></h2>

<p><span class=authors1><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>Silvère M van der Maarel <sup>1</sup>, Antoine de Morrée <sup>1</sup>,
Paul J Hensbergen <sup>2</sup>, Herman HHBM van Haagen <sup>1</sup>, Irina
Dragan <sup>2</sup>, Peter-Bram AC 't Hoen <sup>1</sup>, Rune R Frants <sup>1</sup></span></span><span
style='font-size:9.0pt;font-family:"Helvetica","sans-serif";color:black'> <br>
<span class=affiliations1><sup>1</sup>Department of Human Genetics, Leiden
University Medical Center, Leiden, Netherlands; <sup>2</sup>Department of
Parasitology, Leiden University Medical Center, Leiden, Netherlands</span> </span></p>

<p><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:3.0pt'><img width=115 height=142
src="oral-abstracts-images/image017.jpg" align=left hspace=12
alt="Description: IMG_5622org"><span style='font-size:9.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:black'>Dysferlin is critical for
repair of muscle membranes after damage. Mutations in dysferlin lead to a
progressive muscular dystrophy. Recent studies suggest additional roles for
dysferlin. We set out to study dysferlin’s protein-protein interactions to
obtain comprehensive knowledge of dysferlin functionalities in a myogenic
context. We developed a robust and reproducible method to isolate dysferlin
protein complexes from cells and tissue. We analyzed the composition of these
complexes in cultured myoblasts, myotubes and skeletal muscle tissue by
immunoprecipitation followed by mass spectrometry and subsequently inferred
potential protein functions through bioinformatics analyses. Our data reveal
that the dysferlin protein complex has a dynamic composition as a function of
myogenic differentiation. Our data confirm previously reported interactions and
support a function for dysferlin as a vesicle trafficking protein. In addition
novel potential functionalities are uncovered, including phagocytosis and focal
adhesion. We provide additional experimental evidence and show dysferlin
localization to, and interaction with the focal adhesion protein vinculin at
the sarcolemma. Finally, our studies reveal evidence for the co-existence of
dysferlin and its protein family member myoferlin in single complexes. Together
our analyses show that dysferlin is not only a membrane repair protein but also
important for muscle membrane maintenance and integrity.</span></p>

<h1 style='margin-top:0in'><span style='font-size:12.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:navy'>&nbsp;</span></h1>

<h1 style='margin-top:0in'><span style='font-size:12.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:navy'>Robert J. Bloch, PhD</span></h1>

<p><span class=affiliation11><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>Department of Physiology, University of Maryland School of
Medicine, Baltimore, MD 21201</span></span><span style='font-size:9.0pt;
font-family:"Helvetica","sans-serif";color:black'><br>
</span><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif"'>rbloch@umaryland.edu<span
style='color:black'> </span></span></p>

<h2 style='margin-top:9.0pt'><span style='font-size:9.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:black'>Changes in Dysferlin’s Partners</span></h2>

<p><span class=authors1><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>Robert J. Bloch <sup>1</sup></span></span><span style='font-size:
9.0pt;font-family:"Helvetica","sans-serif";color:black'> <br>
<span class=affiliations1><sup>1</sup>Department of Physiology, University of
Maryland School of Medicine, Baltimore, MD 21201</span> </span></p>

<p><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:3.0pt'><img width=100 height=133
src="oral-abstracts-images/image018.jpg" align=left hspace=13
vspace=13
alt="Description: http://ankurdave.com/jainfoundation/conference2010/abstract-image.php?id=23"><span
style='font-size:9.0pt;line-height:115%;font-family:"Helvetica","sans-serif"'>Western
blotting of detergent-soluble proteins for dysferlin shows no change shortly
after injury, but do show increases of ~ 1.5-fold from d3 through d7
postinjury.  Annexin II increases in immunoblots in parallel with dysferlin,
but neither AHNAK nor caveolin 3 increases significantly postinjury.  Other
membrane-associated proteins are unchanged.  We are currently studying the
distribution of dysferlin by subcellular fractionation of control and injured
muscle, separated on sucrose gradients. </span></p>

<h1 style='margin-top:0in'><span style='font-size:8.5pt;line-height:115%;
font-family:"Verdana","sans-serif";color:black;font-weight:normal'>&nbsp;</span></h1>

<h1 style='margin-top:0in'><span style='font-size:12.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:navy'>&nbsp;</span></h1>

<h1 style='margin-top:0in'><span style='font-size:12.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:navy'>&nbsp;</span></h1>

<h1 style='margin-top:0in'><span style='font-size:12.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:navy'>Rumaisa Bashir, PhD</span></h1>

<p><span class=affiliation11><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>School of Biological and Biomedical Sciences, University of
Durham, South Road, Durham, UK.</span></span><span style='font-size:9.0pt;
font-family:"Helvetica","sans-serif";color:black'><br>
</span><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif"'>rumaisa.Bashir@durham.ac.uk<span
style='color:black'> </span></span></p>

<h2 style='margin-top:9.0pt'><span style='font-size:9.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:black'>ANO5 Protein Expression in
Muscle Cells</span></h2>

<p><span class=authors1><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>Gareth Marlow <sup>1</sup>, Usha Ramachandran <sup>1</sup>,
Michelle M Maxwell <sup>2</sup>, Ibrahim Mahjneh <sup>3</sup>, Rumaisa Bashir <sup>1</sup></span></span><span
style='font-size:9.0pt;font-family:"Helvetica","sans-serif";color:black'> <br>
<span class=affiliations1><sup>1</sup>School of Biological and Biomedical
Sciences, University of Durham, South Road, Durham, UK.; <sup>2</sup>MassGeneral
Institute for Neurodegenerative Disease, Massachusetts General Hospital and
Harvard Medical School, Charlestown, MA, USA; <sup>3</sup>Department of
Neurology, Oulu University Hospital, Oulu, Finland.</span> </span></p>

<p><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:3.0pt'><img width=116 height=117
src="oral-abstracts-images/image019.jpg" align=left hspace=13
vspace=13
alt="Description: http://ankurdave.com/jainfoundation/conference2010/abstract-image.php?id=34"><span
style='font-size:9.0pt;line-height:115%;font-family:"Helvetica","sans-serif";
color:black'>The Anoctamin (ANO) family consists of 10 proteins several of
which have been shown to correspond to the elusive calcium-activated chloride
channels (CaCCs). CaCCs are gated by increases in intracellular calcium and
they have been linked to several cellular functions including epithelial
transport, cell volume regulation, olfactory and photoreceptor transduction,
cardiac membrane excitability, and smooth muscle contraction. The only reported
human mutations linked with the ANO family were dominant mutations in ANO5,
which cause a rare bone fragility disorder gnathodiaphyseal dysplasia (GDD1).
Recently we have identified recessive ANO5 mutations in patients with a distal
non-dysferlin Miyoshi myopathy (MMD3). ANO5 mutations are also linked with a
proximal limb girdle muscular dystrophy (LGMD2L). The clinical heterogeneity
associated with ANO5 mutations is reminiscent of that observed with dysferlin
mutations which can cause both a LGMD and distal muscular dystrophy. ANO5
mutations are associated with loss of muscle membrane integrity and defective
membrane repair. Our studies suggest that ANO5 is a putative calcium-activated
chloride channel which may function with dysferlin in membrane repair. ANO5
shows high skeletal muscle expression which is increased in differentiating
muscle cells and ANO5 is present in vesicles and also resides at the muscle
cell membrane. We are predicting that ANO5 is present in the same vesicle as
dysferlin. To date the identity of the dysferlin vesicles involved in membrane
repair/secretion has not been identified. We have ben testing the suitability
od several ANO5 antibodies and we will present data on the quality of these
antibodies and the expression of ANO5 in wild type and dysferlin deficient
muscle cells. </span></p>

<h1 style='margin-top:0in'><span style='font-size:20.0pt;line-height:115%;
font-family:"Verdana","sans-serif";color:#0F243E'>&nbsp;</span></h1>

<b><span style='font-size:16.0pt;line-height:115%;font-family:"Verdana","sans-serif"'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal><b><span style='font-size:16.0pt;line-height:115%;
font-family:"Verdana","sans-serif"'>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='margin-top:12.0pt;margin-right:0in;
margin-bottom:12.0pt;margin-left:0in;text-align:center'><b><span
style='font-size:16.0pt;font-family:"Verdana","sans-serif"'>Session VI: What is
the role of inflammation in dysferlinopathy?</span></b></p>

<p class=MsoNormal align=center style='margin-top:12.0pt;margin-right:0in;
margin-bottom:12.0pt;margin-left:0in;text-align:center;line-height:12.0pt'><i><span
style='font-size:8.5pt;font-family:"Verdana","sans-serif";color:black'>Examples:
Characterization of the dysferlin-deficient inflammatory response; contribution
of inflammation to pathology; role of dysferlin in immune cells; etc.</span></i></p>

<p class=MsoNormal style='margin-bottom:3.0pt'><span style='font-size:9.0pt;
line-height:115%;font-family:"Helvetica","sans-serif";color:black'>&nbsp;</span></p>

<h1 style='margin-top:0in'><span style='font-size:12.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:navy'>Eric P Hoffman, PhD</span></h1>

<p><span class=affiliation11><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>Department of Integrative Systems Biology, George Washington
University School of Medicine, Research Center for Genetic Medicine, Children's
National Medical Center</span></span><span style='font-size:9.0pt;font-family:
"Helvetica","sans-serif";color:black'><br>
</span><a href="mailto:ehoffman@cnmcresearch.org"><span class=email><span
style='font-size:9.0pt;font-family:"Helvetica","sans-serif";color:black;
text-decoration:none'>ehoffman@cnmcresearch.org</span></span></a><span
style='font-size:9.0pt;font-family:"Helvetica","sans-serif";color:black'> </span></p>

<h2 style='margin-top:9.0pt'><span style='font-size:9.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:black'>Dysferlin Deficient Muscle as
an Inducer of an Immune Response: Role of IL-1beta and Tlrs</span></h2>

<p><span class=authors1><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>Eric P Hoffman <sup>1</sup>, Kanneboyina Nagaraju <sup>1</sup>,
Andreas Baudy <sup>1</sup>, Rashmi Rawat <sup>1</sup></span></span></p>

<p><span class=affiliations1><sup><span style='font-size:9.0pt;font-family:
"Helvetica","sans-serif";color:black'>1</span></sup></span><span
class=affiliations1><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>Department of Integrative Systems Biology, George Washington University
School of Medicine, Research Center for Genetic Medicine, Children's National
Medical Center</span></span></p>

<p><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:3.0pt'><img width=151 height=126
src="oral-abstracts-images/image020.jpg" align=left hspace=13
vspace=13
alt="Description: http://ankurdave.com/jainfoundation/conference2010/abstract-image.php?id=1"><span
style='font-size:9.0pt;line-height:115%;font-family:"Helvetica","sans-serif"'>We
studied the inflammasome molecular platform in dysferlin-deficient human and
mouse muscle. Components of the NACHT, LRR and PYD-containing proteins (NALP)-3
inflammasome pathway were specifically up-regulated and activated in
dysferlin-deficient but not in dystrophin-deficient and normal muscle. Normal
primary skeletal muscle cells were capable of secreting IL-1beta in response to
combined treatment with lipopolysaccharide and the P2X7 receptor agonist,
benzylated ATP, suggesting that not only immune cells but also muscle cells can
actively participate in inflammasome formation. In addition, we show that
dysferlin-deficient primary muscle cells express toll-like receptors (TLRs;
TLR-2 and TLR-4) and can efficiently produce IL-1beta in response to
lipopolysaccharide and benzylated ATP. These data indicate that skeletal muscle
is an active contributor of IL-1beta and strategies that interfere with this pathway
may be therapeutically useful for patients with limb girdle muscular dystrophy
type 2B.</span></p>

<h1 style='margin-top:0in'><span style='font-size:12.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:navy'>&nbsp;</span></h1>

<h1 style='margin-top:0in'><span style='font-size:12.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:navy'>Joseph A Roche, PhD</span></h1>

<p><span class=affiliation11><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>Department of Physiology, University of Maryland School of
Medicine, Baltimore, MD, USA</span></span><span style='font-size:9.0pt;
font-family:"Helvetica","sans-serif";color:black'><br>
</span><a href="mailto:jroche@som.umaryland.edu"><span class=email><span
style='font-size:9.0pt;font-family:"Helvetica","sans-serif";color:black;
text-decoration:none'>jroche@som.umaryland.edu</span></span></a><span
style='font-size:9.0pt;font-family:"Helvetica","sans-serif";color:black'> </span></p>

<h2 style='margin-top:9.0pt'><span style='font-size:9.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:black'>Myofiber Necrosis Precedes
Macrophage Infiltration in Dysferlin-Null Muscle Injured by Large-Strain
Lengthening Contractions</span></h2>

<p><span class=authors1><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>Joseph A Roche <sup>1</sup>, Mohan E Tulapurkar <sup>2</sup>, Lisa
W Ru <sup>1</sup>, Nico VanRooijen <sup>3</sup>, Richard M Lovering <sup>1</sup>,
Jeffrey D Hasday <sup>2</sup>, Robert J Bloch <sup>1</sup></span></span><span
style='font-size:9.0pt;font-family:"Helvetica","sans-serif";color:black'> <br>
<span class=affiliations1><sup>1</sup>Department of Physiology, University of
Maryland School of Medicine, Baltimore, MD, USA; <sup>2</sup>Division of
Pulmonary and Critical Care, University of Maryland School of Medicine,
Baltimore, MD, USA; <sup>3</sup>Department of Molecular Cell Biology, Vrije
Universiteit, Amsterdam, Netherlands</span> </span></p>

<p><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>&nbsp;</span></p>

<p class=MsoNormal><img width=100 height=100
src="oral-abstracts-images/image021.jpg" align=left hspace=13
vspace=13
alt="Description: http://ankurdave.com/jainfoundation/conference2010/abstract-image.php?id=44"> <span
style='font-size:9.0pt;line-height:115%;font-family:"Helvetica","sans-serif"'>The
recovery of dysferlin-null skeletal muscle from injurious large-strain
lengthening contractions is characterized by necrosis, macrophage infiltration
and myogenesis.  Here we characterize the inflammatory response of
dysferlin-null muscle to injury and determine if inflammation precedes necrosis
or vice-versa.  We subjected dysferlin-null A/J mice and control A/WySnJ mice
to large-strain injury and examined them immediately (~10min), or 3, 6, 12, 24,
48 and 72 hr later.  We report that dysferlin-null and control muscles lose the
same amount of torque after injury and recover similarly up to 3 hr after
injury.  However, unlike control muscles that continue to improve,
dysferlin-null muscles lose torque over the following hours and days, as the
number of necrotic fibers increases.  MRI scans, and permeability of myofibers
to membrane damage markers injected before injury or before harvesting muscle
indicate a lesion that spreads across dysferlin-null muscle over several hours
postinjury.  Neutrophils invade dysferlin-null and control muscles to the same
extent until 6 hr postinjury, after which dysferlin-null muscles have more
neutrophils.  Dysferlin-null muscles are invaded by more macrophages than
control muscles at 3 hr and again from 24-72 hr after injury.  Cytokine
profiling shows a ~5-fold increase in monocyte chemotactic protein 1 (MCP-1)
and macrophage colony stimulating factor (MCSF) in dysferlin-null compared to
control muscle at 72 hr postinjury.  Treatment with clodronate-incorporated
liposomes significantly diminished macrophage infiltration after injury in
dysferlin-null muscles, but it neither restored torque to the level of control
muscles, nor reduced the number of necrotic fibers 72 hr after injury.  We
conclude that inflammation is a prominent response of dysferlin-null muscle to
injury, but that it is likely to be secondary to necrosis.                     
</span></p>

<p class=MsoNormal><span style='font-size:9.0pt;line-height:115%;font-family:
"Helvetica","sans-serif"'>Supported by a fellowship to JAR and a grant to RJB
from the Jain Foundation.</span></p>

<h1 style='margin-top:0in'><span style='font-size:12.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:navy'>&nbsp;</span></h1>

<h1 style='margin-top:0in'><span style='font-size:12.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:navy'>Eduard Gallardo, PhD</span></h1>

<p><span class=affiliation11><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>Servei de Neurologia i Laboratori de Neurologia Experimental,
Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona</span></span><span
style='font-size:9.0pt;font-family:"Helvetica","sans-serif";color:black'><br>
<span class=email>egallardo@santpau.cat</span> </span></p>

<h2 style='margin-top:9.0pt'><span style='font-size:9.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:black'>Role of Thrombospondin 1 in
Macrophage Inflammation in Dysferlin Myopathy</span></h2>

<p><span class=authors1><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>Noemi De Luna <sup>1</sup>, Eduard Gallardo <sup>1</sup>, Corinne
Sonnet <sup>2</sup>, Benedicte Chazaud <sup>2</sup>, Raul Dominguez-Perles <sup>1</sup>,
Xavier Suarez-Calvet <sup>1</sup>, Romain K Gherardi <sup>2</sup>, Isabel Illa <sup>1</sup></span></span><span
style='font-size:9.0pt;font-family:"Helvetica","sans-serif";color:black'> <br>
<span class=affiliations1><sup>1</sup>Servei de Neurologia i Laboratori de
Neurologia Experimental, Hospital de la Santa Creu i Sant Pau, Universitat
Autònoma de Barcelona; <sup>2</sup>Institut National de la Sante et de la
Recherche Medicale, INSERM U955-E10, Universite Paris XII, 94000 Creteil,
France</span> </span></p>

<p><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:3.0pt'><img width=100 height=130
src="oral-abstracts-images/image022.jpg" align=left hspace=13
vspace=13
alt="Description: http://ankurdave.com/jainfoundation/conference2010/abstract-image.php?id=52"><span
style='font-size:9.0pt;line-height:115%;font-family:"Helvetica","sans-serif";
color:black'>Muscle inflammation can be a prominent feature in several muscular
dystrophies. In dysferlin myopathy, it is mainly composed of macrophages. To
understand the origin of inflammation in dysferlin deficient muscle, we
analyzed soluble factors involved in monocyte chemotaxis released by myoblasts
and myotubes from control and dysferlinopathy patients using a transwell
system. Dysferlin-deficient myotubes released more soluble factors involved in
monocyte chemotaxis compared with controls (p G 0.001). Messenger RNA
microarray analysis showed a 3.2-fold increase of thrombospondin 1 (TSP-1)
expression in dysferlin-deficient myotubes. Retrotranscriptase polymerase chain
reaction analysis, ELISA, and immunohistochemistry confirmed these results.
Dysferlin mRNA knockdown with short-interfering RNA in normal myogenic cells
resulted in TSP-1 mRNA upregulation and increased chemotaxis. Furthermore,
monocytechemotaxis was decreased when TSP-1 was blocked by specificantibodies.
In muscle biopsies from dysferlinopathy patients, TSP-1expression was increased
in muscle fibers but not in biopsies of patients with other myopathies with
inflammation; TSP-1 was seen in some macrophages in all samples analyzed. Taken
together, the data demonstrate that dysferlin-deficient muscle upregulates
TSP-1 in vivo and in vitro and indicate that endogenous chemotactic factors are
crucial to the sustained inflammatory process observed in dysferlinopathies. </span></p>

<h1 style='margin-top:0in'><span style='font-size:12.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:navy'>&nbsp;</span></h1>

<h1 style='margin-top:0in'><span style='font-size:12.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:navy'>Steve Laval, DPhil</span></h1>

<p><span class=affiliation11><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>Institute of Human Genetics, Newcastle University, UK</span></span><span
style='font-size:9.0pt;font-family:"Helvetica","sans-serif";color:black'><br>
</span><a href="mailto:s.h.laval@ncl.ac.uk"><span class=email><span
style='font-size:9.0pt;font-family:"Helvetica","sans-serif";color:black;
text-decoration:none'>s.h.laval@ncl.ac.uk</span></span></a><span
style='font-size:9.0pt;font-family:"Helvetica","sans-serif";color:black'> </span></p>

<h2 style='margin-top:9.0pt'><span style='font-size:9.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:black'>Inflammatory Cell Populations
During Muscle Regenertion in Dysferlinopathy</span></h2>

<p><span class=authors1><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif"'>Yen-Hui
Chiu <sup>1</sup>, Louise Helskov </span></span><span style='font-size:9.0pt;
font-family:"Helvetica","sans-serif"'>Jørgensen</span><span class=authors1><sup><span
style='font-size:9.0pt;font-family:"Helvetica","sans-serif"'> 1,2</span></sup></span><span
class=authors1><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif"'>,
Lars Klinge<sup>2,3</sup>, Steve Laval<sup>1</sup>, Volker Straub<sup>1</sup>,
Hanns Lochm</span></span><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif"'>ül</span><span
class=authors1><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif"'>ller<sup>1</sup>
Kate Bushby <sup>1</sup></span></span><span style='font-size:9.0pt;font-family:
"Helvetica","sans-serif"'> <br>
<span class=affiliations1><sup>1</sup>Institute of Human Genetics, Newcastle
University, UK; <sup>2</sup>Department of Clinical Pathology, Odense University
Hospital, University of Southern Denmark; </span> <span class=affiliations1><sup>3</sup>Department
of Pediatrics, University of </span></span><span style='font-size:9.0pt;
font-family:"Helvetica","sans-serif"'>Göttingen, Germany</span></p>

<p><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:3.0pt'><img width=115 height=100
src="oral-abstracts-images/image023.jpg" align=left hspace=13
vspace=13
alt="Description: http://ankurdave.com/jainfoundation/conference2010/abstract-image.php?id=2"><span
style='font-size:9.0pt;line-height:115%;font-family:"Helvetica","sans-serif";
color:black'>Muscle regeneration is a complex, multi-stage process involving
multiple cell types, including inflammatory cells. Persistent inflammation, a
distinctive feature of dysferlinopathy may be explained by a stalled
regenerative process in muscle. Failure to successfully conclude muscle regeneration
leads to persistent necrotic fibres and inflammation.<b> </b></span><span
style='font-size:9.0pt;line-height:115%;font-family:"Helvetica","sans-serif"'>Studies
in mice using notexin to induce muscle regeneration indicate a delayed
recruitment of inflammatory cells to injured dysferlin-deficient muscle and
changes in the inflammatory cell populations as the muscle repairs. Repeated
rounds of regeneration may explain the late onset and inflammatory character of
dysferlinopathy</span><span style='font-family:"Helvetica","sans-serif"'>.</span></p>

<p class=MsoNormal style='margin-bottom:3.0pt'><b><span style='font-size:9.0pt;
line-height:115%;font-family:"Helvetica","sans-serif"'>&nbsp;</span></b></p>

<h1 style='margin-top:0in'><span style='font-size:12.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:navy'>Simone Spuler, MD</span></h1>

<p><span class=affiliation11><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>Muscle Research Unit, Experimental and Clinical Research Center,
Charité and Max Delbrück Center, Berlin, Germany</span></span><span
style='font-size:9.0pt;font-family:"Helvetica","sans-serif";color:black'><br>
</span><a href="mailto:simone.spuler@charite.de"><span class=email><span
style='font-size:9.0pt;font-family:"Helvetica","sans-serif";color:black;
text-decoration:none'>simone.spuler@charite.de</span></span></a><span
style='font-size:9.0pt;font-family:"Helvetica","sans-serif";color:black'> </span></p>

<h2 style='margin-top:9.0pt'><span style='font-size:9.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:black'>Increased Susceptibility to
Complement Attack in Dysferlin Deficient Muscle</span></h2>

<p><span class=authors1><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>Katrin Wenzel <sup>1</sup>,Simone Spuler <sup>1</sup></span></span><span
style='font-size:9.0pt;font-family:"Helvetica","sans-serif";color:black'><br>
<span class=affiliations1><sup>1</sup>Muscle Research Unit, Experimental and
Clinical Research Center, Charité and Max Delbrück Center, Berlin, Germany; <sup>2</sup>Muscle
Physiology, Max Delbrück Center, Berlin, Germany</span> </span></p>

<p><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><img width=105 height=116
src="oral-abstracts-images/image024.jpg" align=left hspace=12
alt="Description: sspuler photo"> <span style='font-size:9.0pt;font-family:
"Helvetica","sans-serif"'>Dysferlinopathy is commonly associated with
inflammatory changes in muscle. We found downregulation of  the complement
inhibitor CD55 in skeletal muscle but not in heart of three dysferlin deficient
muscle strains (SJL/J, A/J, Dysf-/-) on mRNA and protein level. The finding was
confirmed on muscle biopsy specimens from dysferlinopathy patients. Myotubes
from dysferlinopathy patients were more susceptible to complement attack than
normal controls.</span></p>

<p class=MsoNormal style='margin-bottom:3.0pt'><span style='font-size:9.0pt;
line-height:115%;font-family:"Helvetica","sans-serif";color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'>&nbsp;</p>

<h1 style='margin-top:0in'><span style='font-size:12.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:navy'>&nbsp;</span></h1>

<h1 style='margin-top:0in'><span style='font-size:12.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:navy'>Renzhi Han, PhD</span></h1>

<p><span class=affiliation11><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>Department of Cell and Molecular Physiology, Loyola University
Medical Center, Maywood, IL 60153</span></span><span style='font-size:9.0pt;
font-family:"Helvetica","sans-serif";color:black'><br>
</span><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif"'>renhan@lumc.edu<span
class=email><span style='color:black'> </span></span></span></p>

<h2 style='margin-top:9.0pt'><span style='font-size:9.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:black'>The Role of the Complement
System in the Disease Progression of Dysferlinopathy</span></h2>

<p><span class=authors1><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>Renzhi Han <sup>1</sup></span></span><span style='font-size:9.0pt;
font-family:"Helvetica","sans-serif";color:black'> <br>
<span class=affiliations1><sup>1</sup>Department of Cell and Molecular
Physiology, Loyola University Medical Center, Maywood, IL 60153</span></span></p>

<p><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:3.0pt'><img width=125 height=124
src="oral-abstracts-images/image025.jpg" align=left hspace=12
alt="Description: Renzhi Han.jpg"><span style='font-size:9.0pt;line-height:
115%;font-family:"Helvetica","sans-serif"'>Mutations in the <i>dysferlin</i>
gene lead to the development of autosomal recessive muscle-wasting disorders
denoted as dysferlinopathies. Dysferlin has been shown to play roles in muscle
repair and muscle regeneration. However, the mechanism by which muscle becomes
dystrophic in these disorders is not fully understood. Lengthening contractions
may cause muscle damage, but we found that dysferlin-deficient extensor
digitarum longus muscles were equally as resistant as normal muscles to seven
40% lengthening contractions. In addition, no dramatic change in the serum
creatine kinase (CK) levels was observed in the 2-month-old (pre-pathological)
dysferlin-deficient mice after 30-min down-hill exercise. Although muscle
inflammation is widely recognized in dysferlinopathy, the contribution from the
immune system to the pathology of dysferlinopathy needs to be explored. Our
recent data showed that the complement system may contribute to the muscle
pathology in dysferlinopathy. We are further investigating the therapeutic
potential of the complement regulators in dysferlinopathy. </span></p>

<p class=MsoNormal style='margin-bottom:3.0pt'><span style='font-size:9.0pt;
line-height:115%;font-family:"Helvetica","sans-serif"'>&nbsp;</span></p>

<b><span style='font-size:16.0pt;line-height:115%;font-family:"Verdana","sans-serif"'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal><b><span style='font-size:16.0pt;line-height:115%;
font-family:"Verdana","sans-serif"'>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-top:12.0pt;margin-right:0in;margin-bottom:
12.0pt;margin-left:0in'><b><span style='font-size:16.0pt;font-family:"Verdana","sans-serif"'>Session
VII: Is there a regeneration defect in dysferlinopathy?</span></b></p>

<p class=MsoNormal align=center style='margin-top:12.0pt;margin-right:0in;
margin-bottom:12.0pt;margin-left:0in;text-align:center;line-height:12.0pt'><i><span
style='font-size:8.5pt;font-family:"Verdana","sans-serif"'>Examples: Ex vivo
characterization of myoblast fusion, proliferation; in vivo assays for myoblast
fusion, stem cell turnover; role of dysferlin in regeneration (e.g. fusion,
signaling); etc.</span></i></p>

<h1 style='margin-top:0in'><span style='font-size:20.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:navy'>&nbsp;</span></h1>

<h1 style='margin-top:0in'><span style='font-size:12.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:navy'>Tatiana V Cohen, PhD</span></h1>

<p><span class=affiliation11><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>Center for Genetic Medicine, Children’s National Medical Center,
111 Michigan Avenue, NW. Washington, DC USA</span></span><span
style='font-size:9.0pt;font-family:"Helvetica","sans-serif";color:black'><br>
</span><a href="mailto:tcohen@cnmcresearch.org"><span class=email><span
style='font-size:9.0pt;font-family:"Helvetica","sans-serif";color:black;
text-decoration:none'>tcohen@cnmcresearch.org</span></span></a><span
style='font-size:9.0pt;font-family:"Helvetica","sans-serif";color:black'> </span></p>

<h2 style='margin-top:9.0pt'><span style='font-size:9.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:black'>Mutations in Dysferlin Result
in Defective Myotube Fusion in Mouse Muscle Cultures</span></h2>

<p><span class=authors1><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>Tatiana V Cohen <sup>1</sup>, Jonathan E Cohen <sup>1</sup>,
Terence A Partridge <sup>1</sup></span></span><span style='font-size:9.0pt;
font-family:"Helvetica","sans-serif";color:black'> <br>
<span class=affiliations1><sup>1</sup>Center for Genetic Medicine, Children’s
National Medical Center, 111 Michigan Avenue, NW. Washington, DC USA</span> </span></p>

<p><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:3.0pt'><img width=105 height=111
src="oral-abstracts-images/image026.jpg" align=left hspace=13
vspace=13
alt="Description: http://ankurdave.com/jainfoundation/conference2010/abstract-image.php?id=20"><span
style='font-size:9.0pt;line-height:115%;font-family:"Helvetica","sans-serif";
color:black'>Dysferlin is involved in membrane repair. Recent investigations
demonstrate poor fusion and low myogenin expression in myoblasts from
dysferlinopathy patients, suggesting that dysferlin may play a role in
myogenesis. On the other hand, pre-symptomatic dysferlinopathy patients have
normal sized muscle. To better understand the role of dysferlin in muscle, we
investigated myofusion in mouse models of dysferlinopathy. Examining primary
myoblast cultures from SJL mice we found that whereas myotubes formed in SJL
muscle cultures, their diameters were smaller and they contained fewer
myonuclei than C57Bl6. The decreased myofusion was not restricted to SJL for
muscle cultures of A/J mice and C2C12 cells deficient in dysferlin showed a
comparably lower myotube diameters and myonuclear number. The content of
structural protein per nucleus remains normal suggesting that dysferlin
deficiency is the underlying cause of decreased fusion in all three. To
determine the molecular mechanism underlying the defect in myotube fusion, we
are using Q-PCR and proteomic approaches in dysferlin-deficient and wild-type
cells. Comparison of myotubes from wild-type and dysferlin-deficient cultures
using MALDI-TOF proteomics showed downregulation of beta-tubulin 2C chain and
myosin regulatory light chain 2. By Q-PCR we found that muscle structural
genes, including Myh1, Myh4 and Myl6b are down-regulated in dysferlin-deficient
cultured myotubes. These analyses confirm that muscle structural proteins are
down-regulated in dysferlin-deficiency. We also found inflammatory genes
including Nfkbie and Igtp upregulated in dysferlin-deficient muscle. Thus, our
results imply that the disturbance in myogenesis associated with dysferlin
deficiency affects several pathways and is not solely attributable to extrinsic
inflammatory responses as has been suggested by whole animal studies.</span></p>

<h1 style='margin-top:0in'><span style='font-size:12.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:navy'>&nbsp;</span></h1>

<h1 style='margin-top:0in'><span style='font-size:12.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:navy'>Steve Laval, DPhil</span></h1>

<p><span class=affiliation11><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>Institute of Human Genetics, Newcastle University, UK</span></span><span
style='font-size:9.0pt;font-family:"Helvetica","sans-serif";color:black'><br>
</span><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif"'>s.h.laval@ncl.ac.uk<span
style='color:black'> </span></span></p>

<h2 style='margin-top:9.0pt'><span style='font-size:9.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:black'>Variability in the Myogenic
Potential of Dysferlinopathic Myoblasts and Muscle Regeneration in
Dysferlinopathy</span></h2>

<p><span class=authors1><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif"'>Yen-Hui
Chiu <sup>1</sup>, Louise Helskov </span></span><span style='font-size:9.0pt;
font-family:"Helvetica","sans-serif"'>Jørgensen</span><span class=authors1><sup><span
style='font-size:9.0pt;font-family:"Helvetica","sans-serif"'> 1,2</span></sup></span><span
class=authors1><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif"'>,
Morten Ritso<sup>1</sup>, Steve Laval<sup>1</sup>, Volker Straub<sup>1</sup>,
Hanns Lochm</span></span><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif"'>ül</span><span
class=authors1><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif"'>ller<sup>1</sup>,
Kate Bushby <sup>1</sup></span></span><span style='font-size:9.0pt;font-family:
"Helvetica","sans-serif"'> </span></p>

<p><span class=affiliations1><sup><span style='font-size:9.0pt;font-family:
"Helvetica","sans-serif";color:black'>1</span></sup></span><span
class=affiliations1><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>Institute of Human Genetics, Newcastle University, UK;<sup> 2</sup>Present
address: Department of clinical Pathology, Odense University Hospital,
Univeristy of Southern Denmark</span></span></p>

<p><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>&nbsp;</span></p>

<p><img width=114 height=102
src="oral-abstracts-images/image027.jpg" align=left hspace=13
vspace=13
alt="Description: http://ankurdave.com/jainfoundation/conference2010/abstract-image.php?id=2"><span
style='font-size:9.0pt;font-family:"Helvetica","sans-serif"'>Dysferlin-deficient
myoblasts show a range of deficiencies related to fusion and myotube formation.
We have derived various human and mouse myoblast lines deficient in dysferlin. Early
stage myoblasts do not demonstrate any significant difference in myogenic
potential compared to wild-type and we hypothesise that defects in myoblast
fusion arise over time during culturing of dysferlin deficient myoblasts. We
observe an excess of neonatal myosin heavy chain&nbsp;positive fibres&nbsp;in
LGMD2B muscle biopsies when compared to LGMD2A, indicating a muscle
regeneration defect in patients. Further studies in mice have demonstrated a
regeneration defect following notexin induced muscle wounding. This may be
explained by a reduced release of chemotactic factors from injured
dysferlinopathic myotubes affecting muscle regeneration. This may also explain
the development of fusion defects in myoblast cultures over time.</span></p>

<h1 style='margin-top:0in'><span style='font-size:12.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:navy'>&nbsp;</span></h1>

<h1 style='margin-top:0in'><span style='font-size:12.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:navy'>Robert J. Bloch, PhD</span></h1>

<p><span class=affiliation11><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>Department of Physiology, University of Maryland School of
Medicine, Baltimore, MD 21201</span></span><span style='font-size:9.0pt;
font-family:"Helvetica","sans-serif";color:black'><br>
</span><a href="mailto:rbloch@umaryland.edu"><span class=email><span
style='font-size:9.0pt;font-family:"Helvetica","sans-serif";color:black;
text-decoration:none'>rbloch@umaryland.edu</span></span></a><span
style='font-size:9.0pt;font-family:"Helvetica","sans-serif";color:black'> </span></p>

<h2 style='margin-top:9.0pt'><span style='font-size:9.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:black'>Dysferlin Null Muscle Does
Not Show a Regeneration Defect after <i>In Vivo</i> Contraction-Induced Injury</span></h2>

<p><span class=authors1><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>Robert J. Bloch <sup>1</sup></span></span><span style='font-size:
9.0pt;font-family:"Helvetica","sans-serif";color:black'> <br>
<span class=affiliations1><sup>1</sup>Department of Physiology, University of
Maryland School of Medicine, Baltimore, MD 21201</span> </span></p>

<p><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:3.0pt'><img width=100 height=119
src="oral-abstracts-images/image028.jpg" align=left hspace=13
vspace=13
alt="Description: http://ankurdave.com/jainfoundation/conference2010/abstract-image.php?id=23"><span
style='font-size:9.0pt;line-height:115%;font-family:"Helvetica","sans-serif"'>We
have examined A/J mice at 1 year of age, to learn if regeneration of muscle
after physiological injury is impaired.  We report that even after 2 rounds of
muscle damage and regeneration induced by 2 separate bouts of injurious,
large-strain contractions, there is no apparent regeneration defect in A/J
muscle.</span></p>

<p class=MsoNormal><span style='font-size:9.0pt;line-height:115%;font-family:
"Helvetica","sans-serif"'> </span></p>

<p class=MsoNormal><span style='font-size:9.0pt;line-height:115%;font-family:
"Helvetica","sans-serif"'>&nbsp;</span></p>

<h1 style='margin-top:0in'><span style='font-size:12.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:navy'>&nbsp;</span></h1>

<h1 style='margin-top:0in'><span style='font-size:12.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:navy'>&nbsp;</span></h1>

<h1 style='margin-top:0in'><span style='font-size:12.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:navy'>Isabelle Richard, PhD</span></h1>

<p><span class=affiliation11><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif"'>Généthon,
CNRS, Evry, France</span></span><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif"'><br>
richard@genethon.fr </span></p>

<h2 style='margin-top:9.0pt'><span style='font-size:9.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:windowtext'>Evaluation of
Regenerative Capacity of Muscles Over-expressing Myoferlin</span></h2>

<p><span class=authors1><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif"'>Carinne
Roudaut <sup>1</sup>, Marina Pryadkina<sup>1</sup>, Rumaisa Bashir<sup>2</sup>,
Isabelle Richard<sup>1</sup></span></span><span style='font-size:9.0pt;
font-family:"Helvetica","sans-serif"'><br>
<span class=affiliations1><sup>1</sup>Généthon, CNRS, Evry, France; <sup>2</sup>School
of Biological and Biomedical Sciences, University of Durham, Durham, UK</span> </span></p>

<p><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif"'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:3.0pt'><img width=100 height=119
src="oral-abstracts-images/image029.jpg" align=left hspace=13
vspace=13
alt="Description: http://ankurdave.com/jainfoundation/conference2010/abstract-image.php?id=6"><span
style='font-size:9.0pt;line-height:115%;font-family:"Helvetica","sans-serif"'> Transgenic
mice over-expressing myoferlin are fertile, produced normal litter size and
show no muscle abnormalities. However, most of their muscles display an
increase of fiber size, consistently with the observation that muscles of
myoferlin knock-out mice are atrophic. Considering these observations and the
fact the myoferlin was proposed to be implicated in myoblast fusion, we
evaluated the regenerative capacity of muscles overexpressing myoferlin after
notexin injection. Results showed an accelerated regeneration of myoferlin
over-expressing muscles both in a WT and dysferlin-deficient backgrounds.</span></p>

<p class=MsoNormal style='margin-top:12.0pt;margin-right:0in;margin-bottom:
12.0pt;margin-left:0in;line-height:12.0pt'><span style='font-size:8.5pt;
font-family:"Verdana","sans-serif";color:black'>&nbsp;</span></p>

<b><span style='font-size:18.0pt;line-height:115%;font-family:"Verdana","sans-serif"'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal><b><span style='font-size:18.0pt;line-height:115%;
font-family:"Verdana","sans-serif"'>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='margin-top:12.0pt;margin-right:0in;
margin-bottom:12.0pt;margin-left:0in;text-align:center'><b><span
style='font-size:18.0pt;font-family:"Verdana","sans-serif"'>Session VIII: How
do we put dysferlin back?</span></b></p>

<p class=MsoNormal align=center style='margin-top:12.0pt;margin-right:0in;
margin-bottom:12.0pt;margin-left:0in;text-align:center;line-height:12.0pt'><i><span
style='font-size:8.5pt;font-family:"Verdana","sans-serif"'>Examples: Gene
therapy, viral or non-viral; gene editing; stem cell therapy; etc.</span></i></p>

<h1 style='margin-top:0in'><span style='font-size:12.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:navy'>&nbsp;</span></h1>

<h1 style='margin-top:0in'><span style='font-size:12.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:navy'>Nicolas Levy, MD, PhD</span></h1>

<h1 style='margin-top:0in'><span style='font-size:12.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:navy'>Marc Bartoli, MD, PhD</span></h1>

<p><span class=affiliation11><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>Department of Medical Genetics, APHM-CHU Timone and INserm UMR910,
</span></span><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif"'>Université
de la Méditerranée<span class=affiliation11><span style='color:black'>,Marseille,
France </span></span><span style='color:black'><br>
Nicolas.levy@univmed.fr</span></span></p>

<p><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>marc.bartoli@univmed.fr</span></p>

<h2 style='margin-top:9.0pt'><span style='font-size:9.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:black'>Therapeutic strategies based
on DYSF mutational data</span></h2>

<p><span class=authors1><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>Nicolas </span></span><span lang=EN-GB style='font-size:9.0pt;
font-family:"Helvetica","sans-serif"'>Lévy</span><span class=authors1><span
lang=EN-GB style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'> </span></span><span class=authors1><sup><span style='font-size:
9.0pt;font-family:"Helvetica","sans-serif";color:black'>1</span></sup></span><span
class=authors1><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>, Marc Bartoli<sup>1</sup></span></span><span style='font-size:
9.0pt;font-family:"Helvetica","sans-serif";color:black'><br>
<span class=affiliations1><sup>1</sup></span><span class=affiliation11> </span><span
class=affiliation11><span style='font-style:normal'>Department of Medical
Genetics, APHM-CHU Timone and INserm UMR910, </span></span></span><i><span
style='font-size:9.0pt;font-family:"Helvetica","sans-serif"'>Université de la
Méditerranée</span></i><span class=affiliation11><span style='font-size:9.0pt;
font-family:"Helvetica","sans-serif";color:black;font-style:normal'>,Marseille,
France</span></span><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'> </span></p>

<p><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:3.0pt'><img width=103 height=120
src="oral-abstracts-images/image030.jpg" align=left hspace=12
alt="Description: 32-Bartoli"><img width=98 height=120
src="oral-abstracts-images/image031.jpg" align=left hspace=13
vspace=13
alt="Description: http://ankurdave.com/jainfoundation/conference2010/abstract-image.php?id=15"><span
lang=EN-GB style='font-size:9.0pt;line-height:115%;font-family:"Helvetica","sans-serif"'>Particular
mutational data obtained from patients are valuable information regarding
possible therapeutic approaches. In Duchenne muscular dystrophy, the
identification of functional Mini-dystrophins led to the development of
therapeutic strategies such as gene transfer of Mini-dystrophin and
exon-skipping approaches. We have shown previously that a Mini-dysferlin
molecule, identified in a patient with a moderately severe phenotype of
dysferlinopathy, was functional for membrane repair when transferred by AAV
vectors into muscle. We have since further developed this strategy by testing
additional constructs comprising more domains, and are evaluating the various
functions of these Midi-dysferlins. Based on another patient reported with an
in-frame deletion of exon 32, and a very moderate phenotype, we developed an
exon 32 targeted skipping approach. After selection by bioinformatics analysis,
we used five different antisense oligonucleotides in myoblasts generated from
control and patient MyoD transduced fibroblasts. Three selected AONs led to an
efficient exon 32 skipping. </span><span style='font-size:9.0pt;line-height:
115%;font-family:"Helvetica","sans-serif"'>Currently, data from the Leiden
Muscular Dystrophy pages© database and our cohort of patients include 22
patients carrying at least one disease-causing mutation in exon 32.
Disease-causing nonsense or missense mutations as well as short insertions
and/or deletions in <i>DYSF</i> exon 32 could be excised by using the exon 32 -
skipping approach with specific AONs. Such a strategy could be applied to
patients carrying these mutations either at a homozygous, or a compound
heterozygous state in a future clinical trial. Altogether, o</span><span
lang=EN-GB style='font-size:9.0pt;line-height:115%;font-family:"Helvetica","sans-serif"'>ur
findings constitute proofs of concept, and prerequisites for similar
therapeutic strategies for a subset of primary dysferlinopathies.</span></p>

<h1 style='margin-top:0in'><span style='font-size:12.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:navy'>&nbsp;</span></h1>

<h1 style='margin-top:0in'><span style='font-size:12.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:navy'>Isabelle Richard, PhD</span></h1>

<p><span class=affiliation11><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>Généthon, CNRS, Evry, France</span></span><span style='font-size:
9.0pt;font-family:"Helvetica","sans-serif";color:black'><br>
</span><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif"'>richard@genethon.fr<span
style='color:black'> </span></span></p>

<h2 style='margin-top:9.0pt'><span style='font-size:9.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:windowtext'>How to Predict
Therapeutic Efficacy?</span></h2>

<p><span class=authors1><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif"'>Nathalie
Bourg <sup>1</sup>, Marina Pryadkina <sup>1</sup>, François Monjaret <sup>1</sup>,
William Lostal <sup>1</sup>,  Joseph Roche <sup>2</sup>, Robert Bloch <sup>2</sup>,
Perrine Borel <sup>1</sup>, Daniel Stockholm <sup>1</sup>, Isabelle Richard <sup>1</sup>,
</span></span><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif"'><br>
<span class=affiliations1><sup>1</sup>Généthon, CNRS, Evry, France; <sup>2</sup>Univ.
of Maryland, Baltimore, MD, USA</span></span></p>

<p><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif"'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:3.0pt'><img width=100 height=118
src="oral-abstracts-images/image032.jpg" align=left hspace=13
vspace=13
alt="Description: http://ankurdave.com/jainfoundation/conference2010/abstract-image.php?id=6"><span
style='font-size:9.0pt;line-height:115%;font-family:"Helvetica","sans-serif"'> The
objective of this project is to define a sensitive, reproducible and rapid test
that could be predictive of a therapeutic efficiency and that can be used to
compare different strategies. Usually, the evaluation of therapeutic efficiency
is tedious and involves many different parameters at the histological and
functional levels. We are evaluating different tests that involve particularly
stressful conditions for the muscles and that would increase the phenotype
differences between normal and dysferlin deficient mice.</span><span
lang=EN-GB style='font-size:9.0pt;line-height:115%;font-family:"Helvetica","sans-serif"'>
The most relevant assays with respect to difference between wild-type and
dysferlin deficient mice are being used in a side-by-side comparison of </span><span
style='font-size:9.0pt;line-height:115%;font-family:"Helvetica","sans-serif"'>AAV-mediated
transfer of full-length dysferlin by concatemerization and AAV-mediated
transfer of a minidysferlin</span><span lang=EN-GB style='font-size:9.0pt;
line-height:115%;font-family:"Helvetica","sans-serif"'>.</span></p>

<p class=MsoNormal style='margin-bottom:3.0pt'><span lang=EN-GB
style='font-size:9.0pt;line-height:115%;font-family:"Helvetica","sans-serif"'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:3.0pt'><span style='font-size:9.0pt;
line-height:115%;font-family:"Helvetica","sans-serif";color:black'>&nbsp;</span></p>

<h1 style='margin-top:0in'><span style='font-size:12.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:navy'>Matt Hirsch, PhD</span></h1>

<p><span class=affiliation11><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>Gene Therapy Center - University of North Carolina, Chapel Hill,
NC, USA</span></span><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'><br>
</span><a href="mailto:mhirsch@email.unc.edu"><span class=email><span
style='font-size:9.0pt;font-family:"Helvetica","sans-serif";color:black;
text-decoration:none'>mhirsch@email.unc.edu</span></span></a><span
style='font-size:9.0pt;font-family:"Helvetica","sans-serif";color:black'> </span></p>

<h2 style='margin-top:9.0pt'><span style='font-size:9.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:black'>A Quantitative Comparison of
Large Gene Delivery Strategies based on AAV </span></h2>

<p><span class=authors1><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>Matthew Hirsch <sup>1</sup>, R.J. Samulski <sup>1</sup></span></span><span
style='font-size:9.0pt;font-family:"Helvetica","sans-serif";color:black'> <br>
<span class=affiliations1><sup>1</sup>Gene Therapy Center - University of North
Carolina, Chapel Hill, NC, USA</span> </span></p>

<p><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:3.0pt'><img width=100 height=98
src="oral-abstracts-images/image033.jpg" align=left hspace=13
vspace=13
alt="Description: http://ankurdave.com/jainfoundation/conference2010/abstract-image.php?id=43"><span
style='font-size:9.0pt;line-height:115%;font-family:"Helvetica","sans-serif";
color:black'>Recombinant adeno-associated virus (AAV) has proven safe and
effective for the treatment of several human genetic diseases. However, a major
limitation for the widespread application of AAV vectors is imposed by the
biology of the viral particle – AAV capsids can only package DNA genomes less
than 5kb. Unfortunately, this renders AAV vectors deficient for the treatment
of disorders that require large gene supplementation including cystic fibrosis,
hemophilia A as well as LGMD2B and Miyoshi myopathies. However, advancements in
AAV vector biology have demonstrated the possibility to overcome the AAV size
limitation by relying on the intracellular reconstruction of a large gene from
smaller genetic elements delivered by distinct AAV capsids. Currently, the most
efficient approach is termed “trans-splicing” or “split” AAV vectors which,
despite inherent inefficiencies, has already demonstrated partial therapeutic
efficacy in models of muscular dystrophies. Recent observations have discovered
a new type of AAV vector in which the capsids are packaged with prematurely
truncated genomes less than 5kb (fragment AAV vectors). In this work, we
characterized these vectors and investigated the cellular mechanisms
controlling large gene reconstruction following fragment vector transduction.
In addition, we analyzed the performance of such vectors for large gene
delivery in vivo. Remarkably, muscle transduction by fragment vectors
approached the efficiency of AAV intact vector transduction at a high, yet
therapeutically relevant, multiplicity of infection. Quantitative experiments
comparing the efficiency of muscle transduction by intact, fragment, and split
AAV vectors are in progress. The AAV large gene delivery method deemed most
efficient will then be employed, using a codon optimized dysferlin gene, and
investigated for phenotypic disease correction in a mouse model of
dysferlinopathy.</span></p>

<h1 style='margin-top:0in'><span style='font-size:12.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:navy'>&nbsp;</span></h1>

<h1 style='margin-top:0in'><span style='font-size:12.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:navy'>Jordi Díaz-Manera, MD</span></h1>

<p><span class=affiliation11><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>1Division of Regenerative Medicine, San Raffaele Scientific
Institute, Milano, Italy</span></span><span style='font-size:9.0pt;font-family:
"Helvetica","sans-serif";color:black'><br>
<span class=email>jdiazM@santpau.cat</span> </span></p>

<h2 style='margin-top:9.0pt'><span style='font-size:9.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:black'>Partial Dysferlin
Reconstitution by Adult Murine Mesoangioblasts is Sufficient for Full
Functional Recovery in a Murine Model of Dysferlinopathy</span></h2>

<p><span class=authors1><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>Jordi Díaz-Manera <sup>1,2</sup>, Thierry Touvier <sup>1</sup>,
Arianna Dellavalle <sup>1</sup>, Rossana Tonlorenzi <sup>1</sup>, Eduard
Gallardo <sup>2</sup>, Isabel Illa <sup>2</sup>, Yvan Torrente <sup>3</sup>,
Giulio Cossu <sup>1</sup></span></span><span style='font-size:9.0pt;font-family:
"Helvetica","sans-serif";color:black'> <br>
<span class=affiliations1><sup>1</sup>1Division of Regenerative Medicine, San
Raffaele Scientific Institute, Milano, Italy; <sup>2</sup>2Hospital Santa Creu
i Sant Pau, Neuromuscular Diseases Unit, Barcelona, Spain; <sup>3</sup>Stem
Cell Laboratory, Department of Neurological Sciences, Fondazione IRCCS Ospedale
Maggiore Policlinico, Centro Dino Ferrari, Università di Milano, Milano, Italy</span>
</span></p>

<p><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:3.0pt'><img width=100 height=117
src="oral-abstracts-images/image034.jpg" align=left hspace=13
vspace=13
alt="Description: http://ankurdave.com/jainfoundation/conference2010/abstract-image.php?id=54"><span
style='font-size:9.0pt;line-height:115%;font-family:"Helvetica","sans-serif";
color:black'>Background and objective. Mutations in dysferlin gene produce a
muscular dystrophy (MD) in humans. A/J mouse completely lacks dysferlin and
develops a slowly progressive MD. Mesangioblasts are vessel associated progenitors
successfully used for cell therapy in different animal models of MD. Our aim
was to treat a mouse model of dysferlinopathy with transplantation of murine
mesoangioblasts (mMABs). Methods mMABs were obtained from muscles of 2
months-old wild type mice (C57 strain), and labelled with lentiviral vector
expressing nuclear LacZ. Immunosupressed dysferlin deficient mice were
developed crossing A/J and SCID lines. A single intramuscular injection of
5x105 mMABs both in cardiotoxin treated and untreated muscles from 5 months old
mice was firstly performed. In a second experiment, 5x105 mMABs were
transplanted using intraarterial injection. The expression of dysferlin was
detected 3 weeks after the injection using immunofluorescence, Real Time-PCR
and Western-Blot. Function of dysferlin was evaluated using a laser-induced
wounding assay of single fibers isolated from transplanted and non transplanted
mice Results There were no significant differences in progression of symptoms
between A/J-SCID and A/J mice. Dysferlin was found in the membrane of several
LacZ+ muscle fibers . Concentration of the protein reached up to 35% of normal
levels after intramuscular injection, and up to 18% after intraarterial
injection. Functional studies demonstrated a better response of single fibers
to laser induced damage in treated mice. Conclusions Treatment with mMABs
successfully recovered expression and function of dysferlin in A/J-SCID mice,
suggesting that cell therapy with adult-derived MABs may be a promising
therapeuthic option for dysferlinopathy patients. </span></p>

<p class=MsoNormal style='margin-bottom:3.0pt'><span style='font-size:9.0pt;
line-height:115%;font-family:"Helvetica","sans-serif";color:black'>&nbsp;</span></p>

<h1 style='margin-top:0in'><span style='font-size:12.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:navy'>Michele P Calos, PhD</span></h1>

<p><span class=affiliation11><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>Department of Genetics, Stanford University School of Medicine,
Stanford, CA</span></span><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'><br>
</span><a href="mailto:calos@stanford.edu"><span class=email><span
style='font-size:9.0pt;font-family:"Helvetica","sans-serif";color:black;
text-decoration:none'>calos@stanford.edu</span></span></a><span
style='font-size:9.0pt;font-family:"Helvetica","sans-serif";color:black'> </span></p>

<h2 style='margin-top:9.0pt'><span style='font-size:9.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:black'>Assessing the In Vivo
Myogenic Potential of Adipose-Derived Mesenchymal Stem Cells</span></h2>

<p><span class=authors1><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>Michele Calos <sup>1</sup>, Marisa Karow <sup>1</sup>, W. Edward
Jung <sup>1</sup></span></span><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'> <br>
<span class=affiliations1><sup>1</sup>Department of Genetics, Stanford
University School of Medicine, Stanford, CA</span> </span></p>

<p><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:3.0pt'><img width=100 height=101
src="oral-abstracts-images/image035.jpg" align=left hspace=13
vspace=13
alt="Description: http://ankurdave.com/jainfoundation/conference2010/abstract-image.php?id=15"><span
style='font-size:9.0pt;line-height:115%;font-family:"Helvetica","sans-serif";
color:black'>The initial phase of our project involves determining the in vivo
myogenic potential of adipose-derived mesenchymal stem cells (AD-MSC). AD-MSC
are an easily isolated and cultured cell type that could be harvested from
patients in a relatively non-invasive manner. We have verified that AD-MSC from
mice can be readily purified and are an abundant source of MSC. We demonstrated
in vitro differentiation of the AD-MSC into osteoblasts and adipocytes and
verified that the cells have the expected cell surface markers of MSC. Several
studies have reported muscle engraftment of human and mouse AD-MSC in normal
and disease model SJL and mdx mice. To attempt to confirm and extend these
studies rapidly, with more rigorous and quantitative monitoring of in vivo
engraftment, we have purified AD-MSC from FVB transgenic mice that carry the
luciferase and GFP genes. The transgenes are expressed from the CAG promoter
and are expressed in all tissues. Myoblasts were also purified from the
luciferase-GFP mice for use as positive controls for engraftment. Luciferase
live-imaging is used to track intramuscular engraftment of the cells. To avoid
strain-specific immune rejection of the cells, donor cells will initially be
transplanted into unlabelled FVB recipient mice that have been
cardiotoxin-treated to provide a degenerating muscle environment. A/J
recipients will also be tested to provide a more authentic disease environment,
although immune suppression may be necessary in these animals. If significant
engraftment is obtained, we will harvest AD-MSC from A/J donors. Prior to
transplantation, dysferlin gene will be introduced in the presence of phiC31
integrase, for sequence-specific integration into the genome. </span></p>

<b><span style='font-size:16.0pt;line-height:115%;font-family:"Verdana","sans-serif"'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal><b><span style='font-size:16.0pt;line-height:115%;
font-family:"Verdana","sans-serif"'>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='margin-top:12.0pt;margin-right:0in;
margin-bottom:12.0pt;margin-left:0in;text-align:center'><b><span
style='font-size:16.0pt;font-family:"Verdana","sans-serif"'>Session IX: How do
we compensate for dysferlin's absence?</span></b></p>

<p class=MsoNormal align=center style='margin-top:12.0pt;margin-right:0in;
margin-bottom:12.0pt;margin-left:0in;text-align:center;line-height:12.0pt'><i><span
style='font-size:8.5pt;font-family:"Verdana","sans-serif";color:black'>Examples:
Activation of other proteins; drug treatments; modulation of calcium pathways;
myostatin inhibition; etc.</span></i></p>

<p class=MsoNormal style='margin-bottom:3.0pt'><span style='font-size:8.5pt;
line-height:115%;font-family:"Verdana","sans-serif";color:black'>&nbsp;</span></p>

<h1 style='margin-top:0in'><span style='font-size:12.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:navy'>Jeffery D Molkentin, PhD</span></h1>

<p><span class=affiliation11><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>Cincinnati Children’s Hospital</span></span><span
style='font-size:9.0pt;font-family:"Helvetica","sans-serif";color:black'><br>
</span><a href="mailto:jeff.molkentin@cchmc.org"><span class=email><span
style='font-size:9.0pt;font-family:"Helvetica","sans-serif";color:black;
text-decoration:none'>jeff.molkentin@cchmc.org</span></span></a><span
style='font-size:9.0pt;font-family:"Helvetica","sans-serif";color:black'> </span></p>

<h2 style='margin-top:9.0pt'><span style='font-size:9.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:black'>Transgenic Overexpression of SERCA1
Mitigates Muscular Dystrophy in Mdx, Sarcoglycan Null, And TRPC3 Transgenic
Mice</span></h2>

<p><span class=authors1><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>Sanjeewa Goonasekera <sup>1</sup>, Jeff Molkentin <sup>1</sup></span></span><span
style='font-size:9.0pt;font-family:"Helvetica","sans-serif";color:black'> <br>
<span class=affiliations1><sup>1</sup>Cincinnati Children’s Hospital</span> </span></p>

<p><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:3.0pt'><img width=114 height=120
src="oral-abstracts-images/image036.jpg" align=left hspace=13
vspace=13
alt="Description: http://ankurdave.com/jainfoundation/conference2010/abstract-image.php?id=46"><span
style='font-size:9.0pt;line-height:115%;font-family:"Helvetica","sans-serif";
color:black'>The molecular mechanisms leading to myofiber necrosis is debated, although
elevated cytosolic Ca2+ may be a primary and common event. Here we demonstrate
the dystrophic phenotype observed in Mdx and delta-sarcoglycan null (DSG) mice
is dramatically improved by skeletal muscle-specific overexpression of
sarco(endo)plasmic reticulum Ca2+ ATPase (SERCA1) using a transgenic approach.
Moreover, dystrophic disease due to TRPC3 overexpression, and its associated
Ca2+ influx mechanism for myofiber necrosis, was also improved with the SERCA1
transgene. Skeletal muscle from SERCA1 transgenic mice showed significantly
elevated SERCA1 protein levels and 2-4-fold greater Ca2+-ATPase activity, which
enhanced Ca2+ clearance and the amplitude of the transient. Histologically,
quadriceps, diaphragm and soleus muscles were analyzed for percent central
nucleation at 3 months of age, revealing up to a 75% reduction in the three
diseased models with the SERCA1 transgene. A similar decrease in fibrosis was
also observed in the same muscle groups in the diseased models. In addition,
serum creatine kinase levels were significantly reduced in DSG/SERCA1 and
Mdx/SERCA1 TG mice compared to DSG or Mdx alone. Mechanistically, we show that
SERCA1 overexpression corrects a deficit in Ca2+ re-uptake in diseased DSG
myofibers, and it reduces mitochondrial swelling observed in DSG myofibers.
Thus, our results demonstrate that enhanced SR Ca2+ ATPase activity improves
both biochemical and histological evidence of muscle damage observed in three
separate mouse models of MD by presumably increasing the rate of Ca2+ clearance
from the cytosol, coupled with more efficient sequestration of Ca2+ in the SR
and less of a “leak” phenomena. SERCA1 gene therapy could thus be a universal
approach to treat most forms of MD.</span></p>

<h1 style='margin-top:0in'><span style='font-size:12.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:navy'>&nbsp;</span></h1>

<h1 style='margin-top:0in'><span style='font-size:12.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:navy'>Eric P Hoffman, PhD</span></h1>

<p><span class=affiliation11><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>Department of Integrative Systems Biology, George Washington
University School of Medicine, Research Center for Genetic Medicine, Children's
National Medical Center</span></span><span style='font-size:9.0pt;font-family:
"Helvetica","sans-serif";color:black'><br>
</span><a href="mailto:ehoffman@cnmcresearch.org"><span class=email><span
style='font-size:9.0pt;font-family:"Helvetica","sans-serif";color:black;
text-decoration:none'>ehoffman@cnmcresearch.org</span></span></a><span
style='font-size:9.0pt;font-family:"Helvetica","sans-serif";color:black'> </span></p>

<h2 style='margin-top:9.0pt'><span style='font-size:9.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:black'>Preclinical Drug Trials in
Dysferlin Deficient SJL Mice Show Disease Improvement by VBP3, but Exacerbation
by Fasudil</span></h2>

<p><span class=authors1><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>Eric P Hoffman <sup>1</sup>, Sree Rayavarapu <sup>1</sup>, Andreas
Baudy <sup>1</sup>, Jack H Van der Meulen <sup>1</sup> Arpana Sali<sup>1</sup>,
Heather Gordish-Dressman<sup>1</sup>, Susan M. Knoblach <sup>1</sup>, Erica
Reeves <sup>2</sup>, Jesse Damsker <sup>2</sup>, John McCall<sup>3</sup>,
Rashmi Rawat<sup>1</sup>, Tanya Cohen<sup>1</sup>, Beryl Ampong <sup>1</sup>,
Kanneboyina Nagaraju <sup>1</sup></span></span></p>

<p><span class=authors1><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>&nbsp;</span></span></p>

<p><span class=affiliations1><sup><span style='font-size:9.0pt;font-family:
"Helvetica","sans-serif";color:black'>1</span></sup></span><span
class=affiliations1><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>Department of Integrative Systems Biology, George Washington
University School of Medicine, Research Center for Genetic Medicine, Children's
National Medical Center; <sup>2</sup>VBpharm LLC; <sup>3</sup>PharMac LLC</span></span></p>

<p><span class=affiliations1><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>&nbsp;</span></span></p>

<p><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>&nbsp;</span></p>

<p><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:3.0pt'><img width=113 height=104
src="oral-abstracts-images/image037.jpg" align=left hspace=13
vspace=13
alt="Description: http://ankurdave.com/jainfoundation/conference2010/abstract-image.php?id=1"><span
style='font-size:9.0pt;line-height:115%;font-family:"Helvetica","sans-serif"'> We
have systematically determined pre-clinical outcome measures for the SJL/J
mouse strain, &nbsp;and found that grip strength normalized to body weight and
open field activity were the most sensitive and reliable indicators of
functional status in SJL/J mice.&nbsp; We then applied these outcome measures
to pre-clinical trials of two drugs: a) fasudil, a rho-kinase inhibitor and b).
VBP-3. Fasudil treated SJL/J mice showed decreased grip strength, horizontal
activity, and soleus muscle force, compared to untreated SJL/J controls,
suggesting exacerbation of disease.&nbsp; VBP-3 was evaluated because of its
potent NF-kB inhibitory as well as its membrane stabilizing properties in
skeletal muscle cells. We found that VBP-3 increased forelimb grip strength,
hindlimb grip strength. VBP-3 treatment significantly decreased entry of Cy5.5
labeled dextran as assessed by the optical imaging of forelimbs and hindlimbs.
VBP-3 showed none of the side effects associated with prednisolone treatment of
SJL/J, indicating potential as a therapy for LGMD2B.&nbsp;</span></p>

<h1 style='margin-top:0in'><span style='font-size:12.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:navy'>&nbsp;</span></h1>

<h1 style='margin-top:0in'><span style='font-size:12.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:navy'>Noah Weisleder, PhD</span></h1>

<p><span class=affiliation11><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>Protein Therapeutics Division, TRIM-edicine, North Brunswick, New
Jersey, USA</span></span><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'><br>
</span><a href="mailto:nweisleder@trim-edicine.com"><span class=email><span
style='font-size:9.0pt;font-family:"Helvetica","sans-serif";color:black;
text-decoration:none'>nweisleder@trim-edicine.com</span></span></a><span
style='font-size:9.0pt;font-family:"Helvetica","sans-serif";color:black'> </span></p>

<h2 style='margin-top:9.0pt'><span style='font-size:9.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:black'>Protein Therapeutics for
Muscular Dystrophy</span></h2>

<p><span class=authors1><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>Noah Weisleder <sup>1</sup>, Jianjie Ma <sup>1</sup></span></span><span
style='font-size:9.0pt;font-family:"Helvetica","sans-serif";color:black'> <br>
<span class=affiliations1><sup>1</sup>Protein Therapeutics Division,
TRIM-edicine, North Brunswick, New Jersey, USA</span> </span></p>

<p><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:3.0pt'><img width=114 height=134
src="oral-abstracts-images/image038.jpg" align=left hspace=13
vspace=13
alt="Description: http://ankurdave.com/jainfoundation/conference2010/abstract-image.php?id=3"><span
style='font-size:9.0pt;line-height:115%;font-family:"Helvetica","sans-serif";
color:black'>Defective membrane repair is associated with limb girdle muscular
dystrophy (LGMD) that is linked to mutations in dysferlin in human patients.
Several other forms of muscular dystrophy, including Duchenne muscular
dystrophy and dystrophy arising from mutations in the dystroglycan complex have
been linked to membrane fragility. Compromised membrane repair and increased
membrane fragility are distinct mechanisms leading to increased muscle fiber
death, as evidenced by the additive nature of these two pathways. A therapeutic
approach to increase the capacity of muscle cells to reseal their membranes
following physiological levels of mechanical stress could address both of these
mechanisms leading to improvement of the regenerative capacity in muscular
dystrophy. Recent studies show that Mitsuguimin 53 (MG53) is an essential
component of the acute membrane repair machinery. Our data indicate that a
molecular complex formed by MG53, dysferlin and Cav3 is essential for repair of
muscle membrane damage, thus providing a therapeutic target for treatment of
muscular and cardiovascular diseases. In an effort to translate these findings
into therapeutic interventions for human diseases, we formed a biotechnology
company named TRIM-edicine, Inc, based on intellectual properties discovered in
at UMDNJ-Robert Wood Johnson Medical School. Our research and development
effort at TRIM-edicine has provided extensive studies to show that recombinant
MG53 purified from E. coli retains efficient membrane repair function,
supporting the therapeutic value of targeting MG53 in muscular dystrophy and
other human diseases. We have developed in vivo animal model data to show that
intra-muscular delivery of recombinant MG53 can ameliorate cardiotoxin-induced
damage to the muscle fibers. Additional studies show that recombinant MG53 can
have protective effects in rodent models of muscular dystrophy. </span></p>

<h1 style='margin-top:0in'><span style='font-size:12.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:navy'>&nbsp;</span></h1>

<h1 style='margin-top:0in'><span style='font-size:12.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:navy'>Joshua Zimmerberg, MD</span></h1>

<p><span class=affiliation11><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>Program in Physical Biology, National Institute of Child Health
and Human Development</span></span><span style='font-size:9.0pt;font-family:
"Helvetica","sans-serif";color:black'><br>
</span><a href="mailto:joshz@mail.nih.gov"><span class=email><span
style='font-size:9.0pt;font-family:"Helvetica","sans-serif";color:black;
text-decoration:none'>joshz@mail.nih.gov</span></span></a><span
style='font-size:9.0pt;font-family:"Helvetica","sans-serif";color:black'> </span></p>

<h2 style='margin-top:9.0pt'><span style='font-size:9.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:black'>Therapeutic Role of Dietary
Lipids In LGMD2B Muscular Dystrophy</span></h2>

<p><span class=authors1><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>Joshua Zimmerberg <sup>1</sup>, Glen Humphrey <sup>1</sup>,
Chanturiya Alexandr <sup>1</sup>, Paul Blank <sup>1</sup></span></span><span
style='font-size:9.0pt;font-family:"Helvetica","sans-serif";color:black'> <br>
<span class=affiliations1><sup>1</sup>Program in Physical Biology, National
Institute of Child Health and Human Development</span> </span></p>

<p><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:3.0pt'><img width=111 height=108
src="oral-abstracts-images/image039.jpg" align=left hspace=13
vspace=13
alt="Description: http://ankurdave.com/jainfoundation/conference2010/abstract-image.php?id=27"><span
style='font-size:9.0pt;line-height:115%;font-family:"Helvetica","sans-serif";
color:black'>At the heart of suffering in LGMD2B muscular dystrophy is the
death without regeneration of muscle fibers that are not repaired due to the
functional absence of a protein, dysferlin, that is hypothesized to mediate the
fusion of intracellular membrane to the sarcolemma. To treat patients in this
situation, one would like to augment the natural tendency of membranes to
reseal after damage, and minimize the inflammation that impedes regeneration
and magnifies tissue destruction. Since the major component of membrane is
lipid, and dysferlin probably works on lipids, it is reasonable to try to
bypass the requirement for dysferlin by changing the </span><span
style='font-size:9.0pt;line-height:115%;font-family:"Helvetica","sans-serif"'>lipid
composition of the sarcolemma. We are testing the effect of dietary lipids on
membrane<span style='color:black'> repair in primary and cultured muscle
membranes, in rodents.</span></span></p>

<p class=MsoNormal style='margin-bottom:3.0pt'><span style='font-size:9.0pt;
line-height:115%;font-family:"Helvetica","sans-serif";color:black'>&nbsp;</span></p>

<h1 style='margin-top:0in'><span style='font-size:12.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:navy'>H. Lee Sweeney, PhD</span></h1>

<p><span class=affiliation11><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>University of Pennsylvania, School of Medicine</span></span></p>

<p><span class=email><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>lsweeney@mail.med.upenn.edu</span></span></p>

<h2 style='margin-top:9.0pt'><span style='font-size:9.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:black'>Blebbing Assay of Dysferlin
Function in Cultured Myotubes</span></h2>

<p><span class=authors1><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>H. Lee Sweeney <sup>1</sup>, Bing Jing Wang <sup>1</sup>, Zhaohui
Yang <sup>1</sup>, Becky Brisson <sup>1</sup>, Elisabeth R. Barton <sup>1</sup>, 
and Robert H. Brown<sup>2</sup></span></span><span style='font-size:9.0pt;
font-family:"Helvetica","sans-serif";color:black'><br>
<span class=affiliations1><sup>1</sup>University of Pennsylvania, Philadelphia,
PA; <sup>2</sup>University of Massachusetts School of Medicine, Worcester, MA</span></span></p>

<p><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:3.0pt'><img width=113 height=116
src="oral-abstracts-images/image040.jpg" align=left hspace=13
vspace=13
alt="Description: http://ankurdave.com/jainfoundation/conference2010/abstract-image.php?id=27"><span
style='font-size:9.0pt;line-height:115%;font-family:"Helvetica","sans-serif"'>We</span><span
style='font-size:9.0pt;line-height:115%;font-family:"Helvetica","sans-serif"'>
have developed an assay for dysferlin function in cultured skeletal muscle myotubes.
The assay is based on observing membrane blebbing in response to hypotonic
osmotic shock.  We demonstrated that membrane blebbing in response to hypotonic
osmotic shock is a calcium- and dysferlin-dependent process in skeletal muscle
myotubes. The use of adenoviral-driven expression of full-length human
dysferlin resulted in functional rescue of membrane blebbing in A/J mouse and
human dysferlin-deficient (Miyoshi) cultured myotubes. This <i>in vitro</i>
assay may be useful for assessing the ability of potential therapeutics to
rescue dysferlin function.</span></p>

<p class=MsoNormal style='margin-bottom:3.0pt'><span style='font-size:9.0pt;
line-height:115%;font-family:"Helvetica","sans-serif"'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:3.0pt'><span style='font-size:9.0pt;
line-height:115%;font-family:"Helvetica","sans-serif"'>&nbsp;</span></p>

<h1 style='margin-top:0in'><span style='font-size:12.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:navy'>Peter R Serafini</span></h1>

<p><span class=affiliation11><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>Department of Genetics, Children's Hospital Boston, Boston, MA,
USA</span></span><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'><br>
</span><a href="mailto:prserafi@colby.edu"><span class=email><span
style='font-size:9.0pt;font-family:"Helvetica","sans-serif";color:black;
text-decoration:none'>prserafi@colby.edu</span></span></a><span
style='font-size:9.0pt;font-family:"Helvetica","sans-serif";color:black'> </span></p>

<h2 style='margin-top:9.0pt'><span style='font-size:9.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:black'>Zebrafish Model of
Dysferlinopathy</span></h2>

<p><span class=authors1><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>Peter R Serafini <sup>1,2</sup>, Genri Kawahara <sup>1</sup>,
Louis M Kunkel <sup>1</sup></span></span><span style='font-size:9.0pt;
font-family:"Helvetica","sans-serif";color:black'> <br>
<span class=affiliations1><sup>1</sup>Department of Genetics, Children's
Hospital Boston, Boston, MA, USA; <sup>2</sup> Department of Biochemistry,
Colby College, Waterville, ME, USA</span> </span></p>

<p><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:3.0pt'><img width=100 height=88
src="http://ankurdave.com/jainfoundation/conference2010/abstract-image.php?id=63"
align=left hspace=13 vspace=13
alt="Description: http://ankurdave.com/jainfoundation/conference2010/abstract-image.php?id=63"><span
style='font-size:9.0pt;line-height:115%;font-family:"Helvetica","sans-serif";
color:black'>Zebrafish express a number of genes that are orthologs of muscular
dystrophy causative genes, including dysferlin, a gene known to mediate vesicle
fusion to the plasma membrane. Using translation-blocking morpholinos to target
dysferlin in zebrafish, we have designed a study to create a model for studying
dysferlinopathy. Our morpholinos targeted regions containing the 5’
untranslated region and the start codon of zebrafish dysferlin mRNA. Two
different, non-overlapping morpholinos (6 ng) were injected at 1-2 cell stage.
At 1 dpf, fish injected with morpholino 1 or 2 (6 ng each) showed abnormal
muscle organization. At 4 dpf, birefringence assays were conducted to better
view the muscle quality. Fish injected with morpholino 1 or 2 showed abnormal
muscle organization as detected by birefringence assays. The affected fish
appeared to have curved tails and curved somite boundaries compared to embryos
injected with a control morpholino and embryos not injected at all. Close to
50% of fish injected with morpholino 1 and nearly 60% of fish injected with
morpholino 2 showed reduced birefringence. These initial findings seem to
suggest that it may be feasible to create a Dysferlinopathy model fish. In the
future we plan to screen candidate chemicals that have been previously reported
to improve muscle quality in dystrophic fish from the sapje, DMD model fish. </span></p>

<p class=MsoNormal style='margin-bottom:3.0pt'><span style='font-size:9.0pt;
line-height:115%;font-family:"Helvetica","sans-serif"'>&nbsp;</span></p>

<h1 style='margin-top:0in'><span style='font-size:12.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:navy'>Kevin Sonnemann, PhD</span></h1>

<p><span class=affiliation11><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>Zoology Research, University of Wisconsin, Madison, WI</span></span></p>

<p><span class=email><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>kjsonnemann@gmail.com</span></span><span style='font-size:9.0pt;
font-family:"Helvetica","sans-serif";color:black'> </span></p>

<h2 style='margin-top:9.0pt'><span style='font-size:9.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:black'>Using Small Molecule Screens
to Identify Positive Regulators of Membrane Repair</span></h2>

<p><span class=authors1><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>Kevin J Sonnemann <sup>1</sup>, William Bement <sup>1</sup></span></span><span
style='font-size:9.0pt;font-family:"Helvetica","sans-serif";color:black'><br>
<span class=affiliations1><sup>1</sup>Department of Zoology, University of
Wisconsin-Madison</span></span></p>

<p><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:3.0pt'><img width=119 height=135
src="oral-abstracts-images/image041.gif" align=left hspace=12
alt="Description: Sonnemann"><span style='font-size:9.0pt;line-height:115%;
font-family:"Helvetica","sans-serif"'>Our goal is to identify positive
small-molecule effectors of cell wound healing that are able to promote
membrane repair in the absence of dysferlin.  We have utilized the size,
handling, and supply advantages of <i>Xenopus laevis</i> oocytes to develop an
oocyte-based assay able to quickly identify small molecules that stimulate or
inhibit membrane repair in response to a physical or laser-induced wounding. 
The assay involves pre-incubating isolated oocytes with the drug of choice, needle
or laser wounding of each individual cell, and monitoring cell health and
viability 16 hours later.  A preliminary screen of the ~2000 compound Diversity
Set I library using the oocyte assay identified 2 compounds that inhibited
proper wound healing in a dose-dependent manner and were non-toxic.  One of the
inhibitory compounds, “Fusostatin,” was determined to inhibit wound repair by
disrupting membrane fusion events at the injury site.  In order to identify
compounds able to stimulate, promote, or accelerate membrane repair, we
performed “suppressor” screens in search of small molecules able to counteract
or suppress the inhibitory effects of Fusostatin.  We repeated the initial
screen on both the Diversity Set II library and the NIH Clinical Collection
library in the presence of Fusostatin and are currently validating positive
compounds from the screen.  Validated compounds will then be subjected to
toxicity and potency analyses; ultimately, the efficacy of each compound’s
repair properties will be tested by its ability to restore proper sarcolemmal
resealing after laser-induced damage in isolated muscle fibers from
dysferlin-deficient <i>Dysf</i><sup>-/-</sup> mice.</span></p>

<h1 style='margin-top:0in'><span style='font-size:12.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:navy'>&nbsp;</span></h1>

<h1 style='margin-top:0in'><span style='font-size:12.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:navy'>Tina Duong, MPT</span></h1>

<p><span class=affiliation11><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>Research Center for Genetic Medicine, Children’s National Medical
Center, Washington DC</span></span><span style='font-size:9.0pt;font-family:
"Helvetica","sans-serif";color:black'><br>
<span class=email>tduong@cnmcresearch.org</span> </span></p>

<h2 style='margin-top:9.0pt'><span style='font-size:9.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:black'>Exercise Shows Improvement in
Skeletal Muscle Performance and Pathology in AJ Mice</span></h2>

<p><span class=authors1><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>Tina Duong <sup>1</sup>,</span></span><span style='font-size:9.0pt;
font-family:"Helvetica","sans-serif"'> Micaela Lantorno<span class=authors1><sup><span
style='color:black'>1</span></sup><span style='color:black'>, Arpana, Sali,
Jack Vandermeulen, Heather Gordish-Dressman<sup>1</sup>,</span></span> Daniel
Guerron<span class=authors1><sup><span style='color:black'>1</span></sup><span
style='color:black'>, Eric Hoffman <sup>1</sup>,</span></span> Kanneboyina
Nagaraju<span class=authors1><span style='color:black'> <sup>1</sup></span></span><span
style='color:black'><br>
<span class=affiliations1><sup>1</sup>Research Center for Genetic Medicine,
Children’t National Medical Center, Washington, DC</span></span></span></p>

<p><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><img width=94 height=114
src="oral-abstracts-images/image042.jpg" align=left hspace=13
vspace=13
alt="Description: http://ankurdave.com/jainfoundation/conference2010/abstract-image.php?id=28"><span
style='font-size:9.0pt;font-family:"Helvetica","sans-serif"'> Effects of
exercise on dysferlin deficient skeletal muscle are unknown. Therefore we have
assessed effects of 3 different sub-maximal exercise interventions (Voluntary
wheel, Horizontal treadmill, Downhill treadmill) on muscle function in dyferlin
deficient A/J mice for 21 weeks (48 sessions). Endpoint measures included grip
strength, rotarod, specific muscle force, CK and histological parameters for
inflammation, and regeneration/degeneration. Mice subjected to exercise
interventions showed improvement in behavioral and functional tests indicating
that mild low intensity exercise may have a protective effect with ability to
improve muscle function and pathology in AJ mice. </span></p>

<p class=MsoNormal style='margin-bottom:3.0pt'><span style='font-size:9.0pt;
line-height:115%;font-family:"Helvetica","sans-serif"'>&nbsp;</span></p>

<h1 style='margin-top:0in'><span style='font-size:12.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:#000099'>&nbsp;</span></h1>

<h1 style='margin-top:0in'><span style='font-size:12.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:#000099'>François-Jérôme Authier</span><span
style='font-size:12.0pt;line-height:115%;font-family:"Helvetica","sans-serif";
color:#000099'>,</span><span style='font-size:12.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:navy'> MD, PhD</span></h1>

<p><span class=affiliations1><i><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>Inserm U955-E 10 ‘Interactions cellulaires dans le syst</span></i></span><i><span
style='font-size:9.0pt;font-family:"Helvetica","sans-serif"'>è<span
class=affiliations1><span style='color:black'>me neuromuculaire’, Universit</span></span>è<span
class=affiliations1><span style='color:black'> Paris-Est Cr</span></span>è<span
class=affiliations1><span style='color:black'>teil, France</span></span></span></i><span
style='font-size:9.0pt;font-family:"Helvetica","sans-serif";color:black'><br>
</span><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif"'>authier@univ-paris12.fr
<span style='color:black'> </span></span></p>

<h2 style='margin-top:9.0pt'><span style='font-size:9.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:black'>From Dysferlin Deficiency to
Dysferlinopathy: The Janus-Faced Role of Exercise</span></h2>

<p><span class=authors1><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>Olivier Biondi <sup>1</sup>, Alic Marchand <sup>1</sup>, Fabrice
Chretien<sup>1,2</sup>, Guillaume Bassez <sup>1,3</sup>, Nathalie Bourg<sup>1</sup>,
Romain K. Gherardi<sup>1,3</sup>, Isabelle Richard<sup>4</sup>, </span></span><span
style='font-size:9.0pt;font-family:"Helvetica","sans-serif"'>François-Jérôme
AUTHIER<sup>1,3</sup><span class=authors1><span style='color:black'> </span></span></span></p>

<p><span class=authors1><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>&nbsp;</span></span></p>

<p><span class=affiliations1><sup><span style='font-size:9.0pt;font-family:
"Helvetica","sans-serif";color:black'>1</span></sup></span><span
class=affiliations1><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>Inserm U955-E 10 ‘Interactions cellulaires dans le syst</span></span><span
style='font-size:9.0pt;font-family:"Helvetica","sans-serif"'>è<span
class=affiliations1><span style='color:black'>me neuromuculaire’, Universit</span></span>è<span
class=affiliations1><span style='color:black'> Paris-Est Cr</span></span>è<span
class=affiliations1><span style='color:black'>teil, France; <sup>2</sup>Stem
Cells &amp; Development, D</span></span>èpartment de Biologie du Dèveloppement,
Institut Pasteur, Paris, France<span class=affiliations1><span
style='color:black'>; <sup>3</sup>Center de Rranfranrences pour Maladies
Neuromusculaires Garches-Necker-Mondor-Hendaye, CHU Albert Chenevier-Henri
Mondor, APHP, Cr</span></span>èteil, France<span class=affiliations1><span
style='color:black'>; <sup>4</sup>G</span></span>ènèthon-CNRS UMR8587 LAMBE,
Evry, France</span></p>

<p><span class=affiliations1><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>&nbsp;</span></span></p>

<p><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>&nbsp;</span></p>

<p><img width=96 height=105
src="oral-abstracts-images/image043.jpg" align=left hspace=13
vspace=13
alt="Description: http://ankurdave.com/jainfoundation/conference2010/abstract-image.php?id=1"><span
style='font-size:9.0pt;font-family:"Helvetica","sans-serif";color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:3.0pt'><span style='font-size:9.0pt;
line-height:115%;font-family:"Helvetica","sans-serif"'> </span><span
style='font-size:9.0pt;line-height:115%;font-family:"Helvetica","sans-serif"'>Dysferlinopathies
are inherited myopathies characterized by a deficiency in dysferlin, a protein
involved in plasma membrane repair process. Various clinical phenotypes/modes
of presentation are described, including LGMD2B, Myoshi-type distal myopathy, proximodistal
onset, and hyperCKaemia, but no phenotype-genotype correlation has been
identified so far. Another unexplained feature lies in a high proportion of
very active patients, prior onset of symptoms. By subjecting
dysferlin-deficient B6.A/J-Dysf<sup>prmd</sup> mice to long-term eccentric
exercise, we observed that eccentric exercise could exacerbate both the pattern
and the course of dystrophic process. In contrast, long-term concentric
exercise had no deleterious effect and allowed training-induced improvement of
muscle strength. Our results could explain, at least in part, both the
phenotypic diversity and the clinical course of dysferlinopathies, and
highlighted the potential benefits of concentric exercise in the management of
dysferlin deficient patients.</span></p>

<b><span style='font-size:16.0pt;line-height:115%;font-family:"Verdana","sans-serif"'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal><b><span style='font-size:16.0pt;line-height:115%;
font-family:"Verdana","sans-serif"'>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='margin-top:12.0pt;margin-right:0in;
margin-bottom:12.0pt;margin-left:0in;text-align:center'><b><span
style='font-size:16.0pt;font-family:"Verdana","sans-serif"'>Session X: What's
new in diagnostic tools for dysferlinopathy?</span></b></p>

<p class=MsoNormal align=center style='margin-top:12.0pt;margin-right:0in;
margin-bottom:12.0pt;margin-left:0in;text-align:center;line-height:12.0pt'><i><span
style='font-size:8.5pt;font-family:"Verdana","sans-serif";color:black'>Examples:
clinical presentation, new diagnostic assays, etc.</span></i></p>

<h1 style='margin-top:0in'><span style='font-size:12.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:navy'>Eduard Gallardo, PhD</span></h1>

<p class=MsoNormal style='margin-bottom:3.0pt'><span class=affiliation11><span
style='font-size:9.0pt;line-height:115%;font-family:"Helvetica","sans-serif";
color:black'>Servei de Neurologia i Laboratori de Neurologia Experimental,
Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona</span></span><span
style='font-size:9.0pt;line-height:115%;font-family:"Helvetica","sans-serif";
color:black'><br>
</span><a href="mailto:egallardo@santpau.cat"><span style='font-size:9.0pt;
line-height:115%;font-family:"Helvetica","sans-serif"'>egallardo@santpau.cat</span></a></p>

<p class=MsoNormal style='margin-bottom:3.0pt'><span style='font-size:9.0pt;
line-height:115%;font-family:"Helvetica","sans-serif";color:black'>&nbsp;</span></p>

<h2 style='margin-top:0in'><span style='font-size:9.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:black'>Dysferlin Blood Test in the
Differential Diagnosis of Muscular Dystrophies: A Clinical, Genetic and Muscle
Biopsy Analysis of a Case Series.</span></h2>

<p class=MsoNormal style='text-autospace:none'><span class=authors1><span
style='font-size:9.0pt;line-height:115%;font-family:"Helvetica","sans-serif";
color:black'>Eduard Gallardo <sup>1</sup>, Noemi de Luna <sup>1</sup>, Jordi
Diaz-Manera <sup>1</sup>,  Ricardo Rojas-Garc</span></span><span lang=ES
style='font-size:9.0pt;line-height:115%;font-family:"Helvetica","sans-serif"'>í</span><span
class=authors1><span style='font-size:9.0pt;line-height:115%;font-family:"Helvetica","sans-serif";
color:black'>a<sup>1</sup>, Carmen Paradas<sup>2</sup>, B</span></span><span
lang=ES style='font-size:9.0pt;line-height:115%;font-family:"Helvetica","sans-serif"'>á</span><span
class=authors1><span style='font-size:9.0pt;line-height:115%;font-family:"Helvetica","sans-serif";
color:black'>rbara Flix<sup>1</sup>, Lidia Gonz</span></span><span lang=ES
style='font-size:9.0pt;line-height:115%;font-family:"Helvetica","sans-serif"'>á</span><span
class=authors1><span style='font-size:9.0pt;line-height:115%;font-family:"Helvetica","sans-serif";
color:black'>lez-Quereda<sup>3</sup>, </span></span><span lang=ES
style='font-size:9.0pt;line-height:115%;font-family:"Helvetica","sans-serif"'>Karolina
Hankiewicz<sup>1</sup>, Ignasi Gich<sup>4</sup>, </span><span lang=CA
style='font-size:9.0pt;line-height:115%;font-family:"Helvetica","sans-serif"'>Antoine
de Morrée</span><sup><span lang=ES style='font-size:9.0pt;line-height:115%;
font-family:"Helvetica","sans-serif"'>5</span></sup><span lang=CA
style='font-size:9.0pt;line-height:115%;font-family:"Helvetica","sans-serif"'>,
Silvere van der Maarel</span><sup><span lang=ES style='font-size:9.0pt;
line-height:115%;font-family:"Helvetica","sans-serif"'>5</span></sup><span
lang=ES style='font-size:9.0pt;line-height:115%;font-family:"Helvetica","sans-serif"'>,
Isabel Illa<sup>1</sup>.</span><span style='font-size:9.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:black'><br>
<span class=affiliations1><sup>1</sup>Servei de Neurologia i Laboratori de
Neurologia Experimental, Hospital de la Santa Creu i Sant Pau, Universitat
Autònoma de Barcelona; <sup>2</sup></span></span><span lang=ES
style='font-size:9.0pt;line-height:115%;font-family:"Helvetica","sans-serif"'>
Servicio de Neurología, Hospital Universitario Valme, Sevilla and Centro de
Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED);</span><span
class=affiliations1><span lang=ES style='font-size:9.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:black'> </span></span><span
class=affiliations1><sup><span style='font-size:9.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:black'>3</span></sup></span><span
lang=ES style='font-size:9.0pt;line-height:115%;font-family:"Helvetica","sans-serif"'>
Servei de Genètica, Hospital de la Santa Creu i Sant Pau i Institut de Recerca
de HSCSP, Universitat Autònoma, Barcelona and Centro de Investigación en Red de
Enfermedades Raras (CIBERER);</span><span class=affiliations1><sup><span
style='font-size:9.0pt;line-height:115%;font-family:"Helvetica","sans-serif";
color:black'> 4</span></sup></span><span lang=ES style='font-size:9.0pt;
line-height:115%;font-family:"Helvetica","sans-serif"'> Department of
biostatistics, Institut de Recerca Hospital de la Santa Creu i Sant Pau,
Barcelona; </span><sup><span lang=EN-GB style='font-size:9.0pt;line-height:
115%;font-family:"Helvetica","sans-serif"'>5</span></sup><sup><span lang=CA
style='font-size:9.0pt;line-height:115%;font-family:"Helvetica","sans-serif"'>.</span></sup><span
lang=CA style='font-size:9.0pt;line-height:115%;font-family:"Helvetica","sans-serif"'>Department
of Human Genetics</span><span lang=CA style='font-size:9.0pt;line-height:115%;
font-family:"Helvetica","sans-serif"'> </span><span lang=CA style='font-size:
9.0pt;line-height:115%;font-family:"Helvetica","sans-serif"'>Leiden University
Medical Center (LUMC), The Netherlands </span></p>

<h2 style='margin-top:0in'><span style='font-size:9.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:black'>&nbsp;</span></h2>

<p><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>&nbsp;</span></p>

<p class=MsoNormal><img width=100 height=130
src="http://ankurdave.com/jainfoundation/conference2010/abstract-image.php?id=52"
align=left hspace=13 vspace=13
alt="Description: http://ankurdave.com/jainfoundation/conference2010/abstract-image.php?id=52"><span
style='font-size:9.0pt;line-height:115%;font-family:"Helvetica","sans-serif";
color:black'> </span><span style='font-size:9.0pt;line-height:115%;font-family:
"Helvetica","sans-serif";layout-grid-mode:line'>We demonstrate the utility of
the dysferlin blood test compared to genetic analysis and muscle biopsy
findings for the diagnosis and differential diagnosis of proximal and distal
muscular dystrophies. The study includes 106 patients with suspicion of muscular
dystrophy (43 with proximal weakness, 47 distal myopathies, 12 hyperCKemia and
4 inflammatory myopathies) and 80 healthy controls. We found that dysferlin
expression below 20% confirmed the diagnosis of dysferlin myopathy </span><span
style='font-size:9.0pt;line-height:115%;font-family:"Helvetica","sans-serif"'>with
a sensitivity and specificity of 95%. <span style='layout-grid-mode:line'>The
study identified 65/106 subjects with absence or very low levels of the protein
(mean expression 1.8</span></span><span style='font-size:9.0pt;line-height:
115%;font-family:Symbol;layout-grid-mode:line'>±</span><span style='font-size:
9.0pt;line-height:115%;font-family:"Helvetica","sans-serif";layout-grid-mode:
line'>3.7%) while 41/106 had normal expression (mean expression 99.5</span><span
style='font-size:9.0pt;line-height:115%;font-family:Symbol;layout-grid-mode:
line'>±</span><span style='font-size:9.0pt;line-height:115%;font-family:"Helvetica","sans-serif";
layout-grid-mode:line'>9.7%). </span><span style='font-size:9.0pt;line-height:
115%;font-family:"Helvetica","sans-serif"'>Genetic analysis identified two
mutations in 42 of these 65 patients and one mutation in 9. The genetic
analysis was not done in 14/65 cases. Quantification of dysferlin protein in
muscle as well as in monocytes in 28/65 patients and in 2 symptomatic carriers
strongly correlated in all cases. Importantly, in 7/45 with normal levels in
monocytes we found a secondary protein reduction in muscle. These patients
corresponded to two LGMD, one LGMD1A, one polymyositis, two elevated CK, and
one congenital myopathy. <span style='layout-grid-mode:line'>This large series
demonstrates that dysferlin blood test is a consistent biomarker of dysferlin
myopathy muscular dystrophy. Values of expression above the threshold discard
this muscular dystrophy. Due to the phenotypic variability of dysferlin
myopathies, the test should be included early in the algorithm for the diagnosis
of LGMD2, distal myopathies and elevated CK.</span></span></p>

<h1 style='margin-top:0in'><span style='font-size:12.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:navy'>Martin KRAHN, MD</span></h1>

<p style='margin-bottom:12.0pt'><span class=affiliation11><span
style='font-size:9.0pt;font-family:"Helvetica","sans-serif";color:black'>INSERM
UMR910, Université de la Méditerranée, Marseille, France</span></span><span
style='font-size:9.0pt;font-family:"Helvetica","sans-serif";color:black'><br>
</span><a href="mailto:martin.krahn@univmed.fr"><span class=email><span
style='font-size:9.0pt;font-family:"Helvetica","sans-serif";color:black;
text-decoration:none'>martin.krahn@univmed.fr</span></span></a><span
style='font-size:9.0pt;font-family:"Helvetica","sans-serif";color:black'> </span></p>

<p class=MsoNormal style='margin-bottom:12.0pt'><b><span lang=EN-GB
style='font-size:9.0pt;line-height:115%;font-family:"Helvetica","sans-serif"'>Novel
Tools for Large-scale Routine Diagnosis of Primary Dysferlinopathies</span></b></p>

<h2 style='margin-top:9.0pt;margin-right:0in;margin-bottom:0in;margin-left:
.25in;margin-bottom:.0001pt;text-indent:-.25in'><span style='font-size:9.0pt;
line-height:115%;font-family:"Helvetica","sans-serif";color:black'>A.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
style='font-size:9.0pt;line-height:115%;font-family:"Helvetica","sans-serif";
color:black'>The Universal Mutation Database for Dysferlin</span></h2>

<p><span class=authors1><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>Martin Krahn <sup>1</sup>, Gaelle Blandin <sup>1</sup>, Marc
Bartoli <sup>1</sup>, Dalil Hamroun <sup>2</sup>, Christophe Beroud <sup>2</sup>,
Nicolas Levy <sup>1</sup></span></span><span style='font-size:9.0pt;font-family:
"Helvetica","sans-serif";color:black'> <br>
<span class=affiliations1><sup>1</sup>Group of Nicolas Levy, Department of
Medical Genetics, APHM-CHU Timone and INSERM UMR910, Universit</span></span><span
style='font-size:9.0pt;font-family:"Helvetica","sans-serif"'>é de la
Méditerranée, Marseille, France; <span class=affiliations1><sup><span
style='color:black'>2</span></sup></span>Group of Christophe Beroud,
Laboratoire de génétique moléculaire, INSERM U 827, CHU de Montpellier, IURC –
Institut Universitaire de Recherche Clinique, Montpellier, France<span
style='color:black'> </span></span></p>

<p><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:3.0pt'><img width=86 height=111
src="oral-abstracts-images/image044.jpg" align=left hspace=13
vspace=13
alt="Description: http://ankurdave.com/jainfoundation/conference2010/abstract-image.php?id=35"><span
lang=EN-GB style='font-size:9.0pt;line-height:115%;font-family:"Helvetica","sans-serif";
color:black'>The compilation of mutational and clinical data from patients
affected with dysferlinopathy is an essential step towards a better
understanding of the natural course of this disease, and possible inclusion in
future therapeutic clinical trials. </span><span style='font-size:9.0pt;
line-height:115%;font-family:"Helvetica","sans-serif"'>As the French national
reference centre for molecular diagnosis of primary dysferlinopathies, we
developed the Universal Mutation Database for Dysferlin (UMD-DYSF, in
collaboration with Christophe Béroud, Montpellier, France). <span
style='color:black'>A main objective of this Locus-specific database is the
compilation and interactive analysis of mutational data. </span>The database
includes several bioinformatics tools which allow for the statistical analysis
of mutational data. Being confronted at to the recurrent problematic of
interpreting newly identified intronic, missense- or isosemantic-exonic
sequence variants, we integrated in UMD-DYSF specific algorithms for the
prediction of a pathogenicity score, which makes this database a valuable
bioinformatics support for genetic diagnosis in primary dysferlinopathies.  In
its current version, the database includes <span class=rien>699 entries
corresponding to 255 different disease-causing mutations identified in 637
patients worldwide, with direct links to the corresponding publications.</span> 
Being integrated in the Natural History of Dysferlinopathies project, UMD-DYSF
will be used to collect the data obtained in the different collaborating
centers. In collaboration with the Jain Foundation Registry, current
developments aim to further developing UMD-DYSF to reach the status of an
international patient registry according to the guidelines of TREAT-NMD,
including regular updates by patients/physicians on the clinical status of
patients with genetically confirmed dysferlinopathy. </span></p>

<h2 style='margin-top:9.0pt;margin-right:0in;margin-bottom:0in;margin-left:
.25in;margin-bottom:.0001pt;text-indent:-.25in'><span style='font-size:9.0pt;
line-height:115%;font-family:"Helvetica","sans-serif";color:windowtext'>B.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span><span
style='font-size:9.0pt;line-height:115%;font-family:"Helvetica","sans-serif";
color:windowtext'>Exhaustive Mutational Analysis of the Dysferlin Gene </span></h2>

<p><span class=authors1><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif"'>Martin
Krahn <sup>1</sup>, Philippe Negre <sup>1</sup>, Helene Holota <sup>2</sup>,
Nicolas Wein <sup>1</sup>, Beatrice Loriot <sup>2</sup>, Fabrice Lopez <sup>2</sup>,
Francois-Xavier Theodule <sup>2</sup>, Francois Jean Imbert <sup>2</sup>, Marc
Bartoli <sup>1</sup>, Nicolas Levy <sup>1</sup> </span></span><span
style='font-size:9.0pt;font-family:"Helvetica","sans-serif"'><br>
<span class=affiliations1><sup>1</sup>Group of Nicolas Levy, Department of
Medical Genetics, APHM-CHU Timone and INSERM UMR910, Universit</span>é de la
Méditerranée, Marseille, France;<span class=affiliations1><sup> 2</sup></span>Group
of Jean Imbert, TAGC, INSERM U928, <span class=affiliations1>Universit</span>é
de la Méditerranée, Marseille, France</span></p>

<p><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt;line-height:115%;
font-family:"Helvetica","sans-serif"'>A major problematic in the field of
dysferlinopathies is accurate molecular diagnosis with currently used
techniques for mutation screening. In about 10 to 20% of patients, only one
mutation is detected, while in approximately 10% of patients, no mutation is
identified. This problematic may be related to insufficient mutation detection
rates, in particular of “atypical” mutations, and the implication of other
genes. For the detection of large genomic deletions/duplications we are now developing
CGH-microarrays based on the Nimblegen® technology for the detection of such
mutational events. Using positive controls previously identified in our lab
using MLPA®, we validated the efficiency of 2.1M probe CGH-microarrays, at a
resolution allowing for the characterisation of corresponding genomic
breakpoints. In parallel, we are developing a combinatory approach of Sequence
Capture arrays coupled to Next Generation Sequencing for dysferlin mutational
analysis. Using 385k Nimblegen array capture and subsequent SOLiD high-throughput
sequencing for five previously characterized patient samples, we validated the
efficiency of this approach for the detection of substitutions and small
insertions/deletions in the dysferlin locus. We will further develop this
approach for future diagnostics sequence applications of the entire dysferlin
locus including “deep intronic” regions, and the analysis of dysferlin related
candidate genes.  </span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt;line-height:115%;
font-family:"Helvetica","sans-serif"'>&nbsp;</span></p>

<h1 style='margin-top:0in'><span style='font-size:12.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:navy'>Ibrahim Mahjneh, MD, PhD</span></h1>

<p><span class=affiliation11><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>Department of Neurology, Univ. of Oulu and MHSO, Oulu, Finland</span></span><span
style='font-size:9.0pt;font-family:"Helvetica","sans-serif";color:black'><br>
</span><a href="mailto:ibrahim.mahjneh@mhso.fi"><span class=email><span
style='font-size:9.0pt;font-family:"Helvetica","sans-serif";color:black;
text-decoration:none'>ibrahim.mahjneh@mhso.fi</span></span></a><span
style='font-size:9.0pt;font-family:"Helvetica","sans-serif";color:black'> </span></p>

<h2 style='margin-top:9.0pt'><span style='font-size:9.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:black'>The Distal Myopathy with ANO5
Mutation is Very Different from Miyoshi Myopathy</span></h2>

<p><span class=authors1><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>Ibrahim Mahjneh <sup>1</sup>, Rumaisa Bashir <sup>2</sup>,
Marianne de Visser <sup>3</sup>, Wim Linssen <sup>4</sup></span></span><span
style='font-size:9.0pt;font-family:"Helvetica","sans-serif";color:black'> <br>
<span class=affiliations1><sup>1</sup>Department of Neurology, Univ. of Oulu
and MHSO, Oulu, Finland; <sup>2</sup>2School of Biological and Biomedical
Sciences, University of Durham, Durham, UK; <sup>3</sup>Department of
Neurology, Academic Medical Center, Amsterdam, The Netherlands; <sup>4</sup>Department
of Neurology, Saint Lucas Andreas Hospital, Amsterdam, The Netherlands</span> </span></p>

<p><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:3.0pt'><img width=90 height=107
src="oral-abstracts-images/image045.jpg" align=left hspace=13
vspace=13
alt="Description: http://ankurdave.com/jainfoundation/conference2010/abstract-image.php?id=51"><span
style='font-size:9.0pt;line-height:115%;font-family:"Helvetica","sans-serif";
color:black'>Miyoshi myopathy (MM) is characterized by early adult-onset
involvement of the calf muscles and high serum creatine kinase (CK) activity,
and is caused by mutations in the dysferlin gene (MMD1). Two Dutch families
with a clinical picture mimicking MM were linked to chromosome 10p (MMD2). In
two families with non-dysferlin MM phenotype (Dutch and Finnish), we have
recently reported homozygous mutations in the ANO5/TMEM16E gene (MMD3). Through
a long lasting follow-up of these families we were able to delineate the
differences between MM and MMD3. The disease seen in MMD3 patients appears to
be very different from MM. Muscle asymmetric involvement is not seen in MM and
calf pains have been reported only in 17% of MM patients. In MMD3 patients
uncomfortable burning muscle sensation preceded the muscle weakness. Distal
muscles of the forearms were spared in MMD3, and there was no involvement of
the anterior muscles of the legs even after 24 years of disease. MMD3 patients
showed gluteus minimus muscle fat degeneration as MM patients did, but no
involvement of gluteus maximus and medium muscles as it is in MM. The shoulder
and paravertebral muscles were spared in MMD3, while these muscles are very
often involved in MM. The histopathology observed in MMD3 cases differs from
these observed in dysferlinopathy for the lack of inflammation and at EM level
for lack of vesicle accumulation under the sarcolemma. We conclude that the
disease seen in MMD3 is clinically, genetically and histopathologically
distinct from MM. </span></p>

<p class=MsoNormal>&nbsp;</p>

</div>
